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Abstract 
Transmissible spongiform encephalopathies (TSE), also known as prion diseases, 
are fatal neurodegenerative disorders which can affect both in humans and 
animals. They occur as sporadic, infectious or genetic disorders (Prusiner et al.; 
1998). A major feature of these diseases is the conversion of the non-pathogenic 
cellular prion protein (PrPC) into the pathogenic scrapie isoform (PrPSc). This 
isoform has a strong tendency to polymerize, forming amyloid aggregates and 
accumulating in the cells, thus resulting in neurodegeneration. The possible 
mechanisms of the prion conversion reaction into the PrPSc are still unknow; and 
could be involved other cellular factors which could trigger, enhance, or accelerate 
scrapie prion formation. An important role has been proposed for the 37/67 kDa 
laminin receptor in prion infections, since it has been shown to act as the receptor 
for both PrPC and PrPSc (Reiger et al.; 1999, Gauczynski et al.; 2001). Moreover, 
the 37/67 kDa laminin receptor is required for PrPSc propagation in cultured cells, 
thus suggesting that 37/67kDa LR-PrPC interaction is related to the pathogenesis 
of prion diseases. As a result, the inhibition of this receptor may be a strategic 
therapy against prion diseases.  
In the first part of my thesis we have investigated the relationship between 
37/67kDa LR and PrPC in the presence of specific LR inhibitor compound. We 
have characterized the trafficking of 37/67kDa LR in both neuronal and non-
neuronal cells, finding the receptor on the cell surface and nuclei, and identified 
the 67kDa LR as the almost exclusive isoform interacting with PrPC. 
Here, we show that the treatment with the 37/67kDa LR inhibitor, NSC47924, 
affects both the direct 37/67kDa LR-PrPC interaction in vitro and the formation of 
the immunocomplex in live cells, inducing a progressive internalization of 
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37/67kDa LR and then its degradation via-lysosomes. On the other hand, PrPC is 
stabilized on the cell surface.  
These data reveal NSC47924 as a useful tool to regulate PrPC and 37/67kDa LR 
trafficking and degradation, representing a novel small molecule to be tested 
against prion diseases.  
Another important issue in prion diseases is the search for a cofactor involved in 
the conversion process of PrPC into PrPSc. Thus, it is important to evaluate the role 
of other genes and proteins in TSE pathogenesis and susceptibility. A very 
promising candidate is Shadoo, a glycosylated GPI-anchored protein like PrPC. It 
is a natively unstructured protein (Watts et al. 2007) that resembles aspects of the 
PrPC N-terminal and central region (Daude et al. 2010). Physiologically, Shadoo 
shows neuroprotective properties similar to those of PrPC (Watts et al. 2007): 
therefore, it is possible that Shadoo and PrPC may be functionally related. Shadoo 
is expressed in the mouse brain less widespread than PrPC and is prominent in two 
regions in which PrPC is notably absent, suggesting that it could provide a PrPC-
like function into areas of the brain in which PrPC is deficient. The downregulation 
of Shadoo expression in the brain of prion-infected animals and the direct in vitro 
interaction between prion protein and Shadoo (Jiayu et al. 2010) suggest a 
relationship between Shadoo and prion replication. However, the contribution of 
this interaction to the evolution of prion pathologies or to the PrPC folding 
pathway remains uncertain (Ciric et al. 2015). Similar to PrPC, Shadoo 
recombinant protein is able to form amyloid assemblies in vitro (Watts et al. 
2010): this feature, however, hasn't been verified in vivo yet. Our laboratory has 
demonstrated that a perturbation of the lipid rafts induces PrPC misfolding 
(Sarnataro et al. 2004), suggesting that they have a protective role in pathological 
conversion of PrPC. Therefore, in the second part of my thesis we have 
characterized Shadoo subcellular localization and folding properties in neuronal 
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cells because we reasoned that, if Shadoo possesses the natural tendency to 
convert to amyloid-like forms in vitro, it should also be able to acquire scrapie-like 
characteristics in live cells also.  
We have found that Shadoo, under native conditions, is partially misfolded in 
neuronal cells. Moreover, lipid rafts perturbation and proteasomal block increased 
misfolding of the protein.  
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1. An Overview on the nature of prions 
 
1.1) Prion diseases and the prion hypothesis  
Prion diseases or also Transmissible Spongiform Encephalopathies (TSEs) are 
fatal neurodegenerative disorders which can occur in both humans and animals. A 
major feature of these diseases is the conversion of the non-pathogenic, cellular 
prion protein (PrPc) into the pathogenic scrapie isoform (PrPSc), (Stahl and 
Prusiner, 1991). This isoform has a strong tendency to polymerize, forming 
amyloid aggregates which accumulate in the brain. The accretion of this abnormal 
protein takes place mainly in the brain and in the lymphoreticular system, 
accompanied with neuronal vacuolation (spongiosis) and neuronal death. After an 
extremely long incubation time, affected individuals show progressive 
neurological symptoms (such as rapid neurological decline involving neuronal 
loss, dementia, loss of movement coordination, and a spongiform degeneration of 
the brain), all terminating with death (Prusiner et al., 1994).  
The Creutzfeldt-Jakob disease (CJD) is the most common type within the human 
prion diseases (Creutzfeldt et al., 1920), which can be classified into four 
categories: sporadic (sCJD), (Jakob et al., 1921), inherited/familial (fCJD), 
(Kirschbaum et al., 1924), iatrogenic (iCJD), (Duffy et al., 1974), and variant 
(vCJD), (Will et al., 1996). It has been suggested that the variant type (vCJD) is 
due to ingestion of BSE-contaminated food; familial disorders (fCJD) are the 
inheritance of autosomal-dominant mutations within the Prnp locus gene. 
Transplantation of tissues or injection of hormones originating from individuals 
suffering from CJD, as well as the use of contaminated surgical instruments, result 
in the iatrogenic form of CJD. Gerstmann-Straussler–Scheinker syndrome (GSS), 
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(Gerstmann et al., 1936), fatal familial insomnia (FFI), (Lugaresi et al., 1986), its 
sporadic form (sFI), (Mastrianni et al., 1999; Parchi et al., 1999), and kuru 
(Gajdusek and Zigas, 1957) are other human prion diseases. Animal TSEs have 
been observed in different species: bovine spongiform encephalopathy (BSE) in 
cattle (Wells et al., 1987), scrapie in sheep, chronic wasting disease (CWD) in 
deer and elk, feline spongiform encephalopathy (FSE) in cats (Wyatt et al., 1990), 
transmissible mink encephalopathy (TME) (Burger and Hartsough, 1965), chronic 
wasting disease in wild ruminants (CWD) (Williams and Young, 1980), (Wells et 
al., 1987), and encephalopathies of a number of zoo animals (exotic ungulate 
encephalopathy, EUE), and transmission of BSE to pigs.   
The different modes of transmission still haven't been understood. Several 
hypotheses about the nature of the infectious agent have been proposed. Initially, 
this agent was thought to be a slow virus (Sigurdsson et al., 1954; Thormar et al., 
1971). However, further research has indicated that the infectious particle was 
substantially different from viruses and other conventional agents. In particular, its 
uncommon resistance to UV radiation and nucleases has led to the proposal that 
the infectious agent was devoid of nucleic acid (Alper et al., 1967; Prusiner et al., 
1982, 1998). In 1967, J. S. Griffith postulated the hypothesis that the causative 
agent might be a protein (Griffith et al., 1967). The theory of a self-propagating 
proteinaceous agent (Bolton et al., 1982) was proposed after the isolation of a 
protease-resistant sialoglycoprotein specifically associated with infectivity, which 
was called the prion protein (PrP) (Bolton et al., 1982).  
The term prion, due to Stanley Prusiner, is the abbreviation for “Proteinaceous 
Infectious Particle” and was defined as a “small proteinaceous infectious particle 
that resists inactivation by procedures which modify nucleic acids” (Bolton et al., 
1982; Prusiner et al., 1982). This newly discovered pathogen (protease-resistant 
prion protein - PrPres - also called PrPSc from scrapie) was isolated from the brain 
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of infected animals (Bolton et al., 1982). Interestingly, infectivity was 
substantially reduced by agents capable of destroying protein structures and by 
anti-PrP antibodies (Gabizon et al., 1988).  
 
1.2)  Cell biology of PrPC: expression and functions 
 
PrPC is a normal cellular protein that is expressed in the neurons and glia of brain 
and spinal cord, but also in several peripheral tissues and leukocytes. In the adult 
central nervous system, PrPC is widely distributed in neocortical and hippocampal 
neurons, cerebellar Purkinje cells and spinal motor neurons (Caughey et al.,1988;  
Bendheim et al., 1992; Hartle et al., 1996). The normal function of PrPC remains 
unknown, although its localization on the cell surface would reflect with roles in 
cell adhesion, ligand uptake or transmembrane signaling. Some PrPC possible 
functions may include: a neuroprotective role due to antiapoptotic activity, 
memory formation and neurogenesis, and a functional role in copper metabolism 
due to its copper binding capacity (Bounhar et al., 2001; Diarra-Mehrpour et al., 
2004). Different proteins including laminin, which is an extracellular protein, N-
CAM, Aa cell surface component with an important role in neuronal aggregation, 
and tyrosine kinase Fyn implicating a role of PrPC in cell signaling (Mouillet-
Richard et al., 2000). PrPC may reduce copper, inducing a protection against 
oxidative stress (Brown et al., 1997). It has been demonstrated that PrPC knockout 
mice exhibit 50% lower copper concentration in synaptosomal fractions than wild-
type mice. Thus, PrPC might regulate the copper concentration in the synaptic 
region and may play a role in the reuptake of copper into the presynapse 
(Kretzschmar et al., 2000). In vivo experiments revealed that protein and lipid 
oxidation is increased in skeletal muscles, heart, and liver of Prnp0/0 mice, 
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suggesting a PrPC function related to cellular antioxidant defenses (Klamt et al., 
2001).  
PrPC may fail to play its normal function when it is converted to PrPSc isoform. 
Mice lacking PrPC (Prnp0/0) show no obvious phenotype; they display no gross 
developmental or anatomical defects, but are reported in some studies to have 
elctrophysiological and structural abnormalities in the hippocampus, loss of 
cerebellar Purkinje cells alterations in circadian rhythm and sleep pattern, and 
changes in learning and memory (Bueler et al., 1992).  
Prnp 0/0 mice and cells derived from these mice are resistant to infection with prion 
agents; primary culture neurons are not killed by the toxicity of prion agents; 
prions cannot proliferate in the brain of Prnp 0/0 (Bueler et al., 1993). Therefore, it 
is clear that PrPC plays an important role in the mechanism of infection and 
contributes to the pathogenesis of prion diseases.  
 
1.3)    Structure and biosynthesis of PrPC 
 
PrPC is a cell surface protein, most of which is found on the plasma membrane and 
does not remain on the cell surface after its delivery there but, rather, 
constitutively cycles between the plasma membrane and endocytic compartment 
via clatrin coated pits-dependent pathway (Harris et al., 1999). Moreover, in our 
laboratory it has been demonstrated that lipid rafts-dependent pathway plays a key 
role in the endocytosis of PrPC in epithelial cells (Sarnataro et al., 2009). PrPC 
undergoes a number of post-traslational modification in the ER and Golgi. After 
cleavage of a 23 amino acid signal peptide in the endoplasmic reticulum (ER), a 
glycosylphosphatidil inositol (GPI) anchor, which mediates its anchoring to the 
membrane, is attached to the C-terminus of the protein (Stahl et al.; 1987). The 
two Cys residues 179 and 214 are engaged in the formation of a disulphide bond 
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essential for the stability of the protein (Haraguchi et al.; 1989; Turk et al., 1988; 
Vana et al., 2006) 
PrPC in the ER is subject to addition of N-linked oligosaccharide chains at two 
asparagine (N) (residues 181 and 197 humans) in the C-terminal part. These chains 
are of high mannose type and are sensitive to the digestion by endoglycosidase-H. 
In the Golgi they are subsequently modified to more complex oligosaccharides 
that contain sialic acid and are resistant to endoglycosidase-H (Caughey et al., 
1989).  
PrPC undergoes two post-traslational cleavages as part of its normal metabolism; 
the first cleavage is proteolytic and occurs within the N-terminal fragment that 
could serve as a biologically active ligand. The second occurs within the GPI 
anchor and releases the polipeptide chain into the cytosol and is specifically 
degraded by the proteasome (Figure 1).  
Like other GPI-anchored proteins (Zurzolo et al., 1994; Lipardi et al., 2000) both 
PrPC and PrPSC have been found enriched in rafts and are typically resistant to 
extraction in Triton X-100 (Taraboulos et al., 1992; Naslavsky et al., 1997; Harris, 
1999) and are able to float in the lighter fractions of sucrose density gradients 
(Sarnataro et al., 2002). Lipid rafts are dynamic lipid assemblies enriched in 
cholesterol and sphingolipids. The raft association of PrPC is mediated by both its 
GPI-anchor and the N-terminal region of its ectodomain. Lipid rafts do not have a 
role in PrPC exocytic trafficking, as is typical for other GPI-anchored proteins 
(Sarnataro et al., 2002), but as shown by us PrPC association with lipid rafts in the 
ER stabilizes its conformation (Sarnataro et al., 2004). An impairment of rafts-
association by cholesterol depletion during the early stage of PrPC biosynthesis 
leads to protein misfolding in ER, suggesting a functional role for rafts in the 
protection of PrPC folding (Sarnataro et al., 2004).    
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1.4)   The pathogenic isoform PrPSc and replication mechanisms 
 
The molecular basis of the conversion of PrPC into a pathogenic isoform PrPSc is 
still unknown. Current evidence suggests that the fundamental difference between 
the two forms of PrP lies in their conformation. PrPC is monomeric and digested 
by proteinase K, whereas PrPSc forms highly insoluble aggregates and shows 
higher resistant to proteolytic digestion.  
The spectroscopic studies demonstrated a conformational difference between PrPC 
and PrPSc, PrPC has a high α-helical content of approx. 42%, with little or no β-
sheets (approx. 3%), whereas PrPSc contains approx. 30% α-helices and approx. 
45% β-sheets (Pan et al., 1993). Because of the lack of antibodies specific to PrPSc, 
the subcellular distribution of has been PrPSc extremely difficult to assess and a 
range of discordant studies indicate that it has a wide distribution, in particular at 
the plasma membrane and in endolysosomal compartment (McKinley et al., 1991; 
Arnold et al., 1995); (Figure 1). Characterizing the exact intracellular localization 
of PrPC and PrPSc is important for identifying the intracellular compartment and 
the mechanisms that underlie prion formation. 
Formation of PrPSc could take place either at the plasma membrane, where the first 
contact between endogenous PrPC and exogenous PrPSc is likely to occur, or 
immediately after its internalization in the endolysosomal or recycling 
compartment (Jaffry et al., 2001; Marjanovic et al., 2009); (Figure 1). Another 
possibility is that after its internalization PrPSc undergoes retrograde transport to 
the Golgi apparatus and/or to the ER, thereby perturbing the biosynthesis of newly 
synthesized prion protein and triggering the formation of the PrPSc isoform from 
the PrPC precursor. Some studies suggest that the ER might have a significant role 
in the conversion of PrPC.  
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Thus, through this compartment a high amount of substrate for the conversion 
reaction travels and it is conceivable that it is easier to transconform the nascent 
polypeptide than to convert mature, correctly folded forms of the protein. 
Involvement of the ER in pathological conversion is also supported by studies in 
which Harris e al., 2003 demonstrated that acquisition of the initial scrapie-related 
features of mutant PrP occurred in the ER (Harris et al., 2003). Furthermore, 
several studies have shown that the ER-associated degradation pathway is both 
involved in the degradation of pathogenic PrP mutants that are linked with familial 
prion diseases and responsible for the normal degradation pathway of misfolded 
PrP isoforms that is, incorrectly folded isoforms of PrPC (Zanusso et al., 19). By 
different studies it has been demonstrated that the ER, plasma membrane and 
endocytic compartments are important in prion formation, but they might be 
differentially involved. The ER could function in amplifying the PrPSc form after 
retrograde transport to the ER.  In genetic prion diseases, by contrast, the ER could 
represent the compartment in which mutant PrP molecules are spontaneously 
transformed to PrPSc or PrPSc-like conformers. 
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Figure 1. Intracellular trafficking of PrPC and PrPSC, and possible pathways of PrPSC 
formation. PrPC is synthesized in the ER, in which it acquires post-translational modifications and 
in which misfolded PrP and hereditary pathological mutants (mutant PrP) are partially degraded by 
the proteasome after retro-translocation through the cytosol. PrPC has also been found in the 
neuronal cytosol and, under some experimental conditions, misfolded PrP aggregates are also 
present in the cytosol. After ER quality control, PrPC is transported through the Golgi apparatus to 
the cell surface, at which it associates with rafts and is internalized by clathrin- and/or caveolin-
dependent mechanisms. Blocking transport of PrPC to the plasma membrane and rerouting it to 
lysosomes for degradation (i), and releasing nascent PrPC from the cell surface (ii) prevent the 
formation of PrPSc. A reduction in PrPC internalization (iii) also decreases PrPSc formation. Both 
PrP isoforms are found in Rab5-positive early endosomes, pass through late endosomes and are 
totally (PrPC) or partially (PrPSc) degraded in acidic lysosomes. Moreover, part of the PrPC pool is 
recycled back to the plasma membrane in a Rab4-dependent pathway, and both PrPC and PrPSc are 
found associated with exosomal membranes in the extracellular medium of infected cells. Finally, 
the ER has been postulated to have a role in prion conversion by amplifying PrPSc formation after 
the Rab6a dependent retrograde transport of PrPC (iv) (Campana et al., 2005).  
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Lipid rafts have been proposed as possible sites for the conversion of PrPC to 
PrPSc. Its role in the formation of PrPSc is inferred from the finding that both PrPC 
and PrPSc are present in rafts extracted from infected cells and from mouse brain 
(Taraboulos et al., 1992; 1995; Botto et al., 2004). The type of rafts associated 
with each isoform has different characteristics (Naslavsky et al., 1997). However, 
lipid rafts have been further implicated in PrPC-PrPSc trans-conformation because 
removing PrPC from rafts by exchanging its GPI-anchor for a transmembrane 
domain prevents the formation of PrPSc (Taraboulos et al., 1995; Kaneko et al., 
1998).  
Conversely, impairing of PrPC rafts association by cholesterol depletion during the 
early stage of its biosynthesis leads to protein misfolded (Sarnataro et al., 2004), 
suggesting that rafts have a protective role in the trans-conformational process.  
A chief issue is how lipid rafts control the formation of PrPSc.  Three models have 
been proposed: i) rafts could be involved in the targeting of PrPC to the specific 
compartment in which PrPSc transconformation occurs; ii) rafts could contain 
machinery that is indispensable for PrPSc formation, such as proteins that facilitate 
its conversion; iii) rafts could provide a favorable environment for 
transconformation by facilitating close encounters between PrPC and PrPSc 
(Campana et al., 2005), (Figure 2).  
Moreover, Marijanovic et al. (2009) characterized the subcellular 
compartmentalization of PrPC and PrPSc in the neuronal infected cell line and 
showed that while PrPC was enriched at the plasma membrane (PM) and in the 
Golgi, PrPSc was found predominantly in the endocytic pathway, in early 
endosomes and late endosomes/lysosomes and specifically enriched in recycling 
endosomes (ERC).  
 
 
20 
 
 
 
 
 
Figure 2. Potential roles of raft association in prion formation. Rafts could be implicated in 
different aspects of prion conversion as indicated by the models shown. (a) Rafts could be the 
vehicle of prion transport to an intracellular compartment, such as the plasma membrane (PM), 
endolysosomes, caveolae or ER, in which the transconformation occurs. (b) Rafts could contain the 
factors (protein X or lipid chaperones) comprising the transconformation machinery. (c) Rafts 
could be a platform on which PrPC accumulation occurs, functioning to promote the encounter 
between PrPC and PrPSc and to enhance the prion conversion reaction (modified by Campana et al., 
2005)  
 
 
1.5)    Prion hypothesis and replication models of prions  
 
In prion diseases, the possible mechanisms of the prion conversion reaction into 
the PrPSc abnormal isoform is unknown. Following the intuition of Griffith (1967), 
that an abnormal infectious protein can propagate by interacting with its normal 
counterpart, “the protein-only hypothesis” proposed that PrPSc amplifies itself by 
converting PrPC to the PrPSc in a reaction that, once started in different cell types 
of the central nervous system (CNS), causes fatal neurodegeneration. The fact that 
administration of a small quantity of PrPSc can induce conversion of the host PrPC 
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and that the ablation of the PrP-encoding gene renders animals resistant to prion 
diseases (Bueler et al., 1993; Brandner et al., 1996), represents the strongest 
evidence in favor of the prion hypothesis. 
However, the infectious agent, PrPSc, alone or its interactor PrPC, are not able to 
reproduce the infection process in vitro. An alternative model, the “unified 
theory” was proposed to incorporate both the protein-only and the protein plus 
nucleic acid hypotheses (Weissmann,1991). According to this model, PrPC- PrPSc 
conversion is the principal pathogenic event, but a co-prion agent such as a small 
host-specified nucleic acid associated with PrPSc a small interfering (si)RNAs and 
microRNAs represent a crucial component required to modulate pathogenic 
conversion (Weissmann, 1991). 
Then, it was proposed the “refolding” model in which PrPC unfolds and refolds 
under the influence of PrPSc (Prusiner, 1991); the nucleation model, or “seeding” 
that describes how PrPC can spontaneously assume different conformations (such 
as PrPC and PrPSc), which are in equilibrium (Come et al., 1993; Harper and 
Lansbury, 1997). In physiological conditions the equilibrium of the reaction 
strongly favors PrPC, because PrPSc conformation acquires high activation energy 
(Come et al., 1993; Harper and Lansbury, 1997). The presence of a PrPSc crystal-
like seed abolishes this energy barrier by stabilizing the PrPSc conformation and by 
promoting the rapid monomer addition of PrPSc to the seed (Jarrettand Lansbury, 
1993). Moreover, the overexpression of PrPC in cell cultures is not sufficient to 
initiate and maintain prion replication (Montrasio et al., 2001), indicating the 
requirement of an auxiliary host factor(s) a “Protein X or Co-Factor for Protein” 
(Enari et al., 2001; Peretz et al., 2001). Weissmann (2004) proposed a dynamic 
susceptibility model, where the capacity of cells to propagate prions would depend 
on a synthesis-degradation equilibrium. If the rate of prion synthesis would not be 
equal or exceed twice the rate of its degradation, prions would be eliminated from 
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cells after infection. Instead, when the rate of scrapie formation is more than twice 
that of its degradation, the high prion accumulation could trigger cell death. Thus, 
the ability of the cell to efficiently sustain prion replication would depend on this 
delicate equilibrium (Weissmann et al.; 2004, Fasano et al.; 2006). 
 
2. 37 /67 kDa LR non-integrin laminin receptor  
2.1) Looking into 37/67 kDa laminin receptor  
The 37/67 kDa human laminin receptor (LamR) is a non-integrin cell surface 
receptor for laminin-1, a variety of viruses (Mercurio et al., 1990) and prion 
protein (Rieger et al., 1997). Because of its wide range of ligands, 37/67kDa LR 
plays a role in numerous pathologies; its over expression correlates with a highly 
invasive cell phenotype and increased metastatic ability, mediated by its 
interactions with laminin-1. In 1983, this receptor for ECM (extracellular matrix) 
glycoprotein laminin was isolated and identified by three different laboratories 
from murine melanome cells (Rao et al., 1983), human breast carcinoma cells and 
normal muscle cells (Lesot et al., 1983). The isolated receptor had an apparent 
molecular mass (as estimated by SDS/PAGE) of approx 67kDa. The receptor 
bound laminin with high affinity and specificity (Montuori, N., & Sobel, M.E, 
1996); consequently, this receptor was named 67LR (67 kDa Laminin Receptor) 
and more recently, LAMR1(laminin receptor 1), (Lesot et al., 1983; Malinoff & 
Wicha, 1983; Rao et al., 1983). Then, cDNA clones encoding for human and 
murine 67 LR were isolated. Unexpectedly, none of the isolated human and 
murine cDNA encoded for a 67kDa protein but for a peptide only 295 amino acid 
long, with a calculated molecular weight of 32 kDa and an apparent 
electrophoretic mobility in SDS-polyacrilamide gel of about 37 kDa. This peptide 
was considered to be the precursor of 67LR and named according to its molecular 
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mass, 37 kDa laminin receptor precursor (37 LRP) (Wewer et al., 1986; Rao et al., 
1989; Castronovo et al., 1991). The mechanism by which 37LRP converts into the 
mature 67LR is incompletely understood. Recent evidences demonstrate that 67 
LR is acylated by fatty acids, suggesting that 37LRP can dimerize with itself or 
with another peptide by strong hydrophobic bonds mediated by fatty acids. 
However, the amino-acid compositions of 67LR and 37LRP are identical, 
suggesting homodimer formation (Buto et al., 1998). Although, the 37LRP reveals 
some interesting and unusual features such as: there are no N-linked carbohydrate- 
attachment sites or typical transmembrane domains; there is no recognized signal 
sequence at the N-terminus for entry and translation in the endoplasmic reticulum. 
However, the N-terminal region contains a hydrophobic segment (aminoacids 86–
101) that has been hypothesized to act as a transmembrane domain. Finally, there 
is an unusual C-terminal 70-amino-acid segment, which is trypsin-resistant and 
highly negatively charged which contains five repeats with the sequence 
(D/E)W(S/T), (Rao et al., 1989; Castronovo et al., 1991; DiGiacomo, V., & 
Meruelo 2015). The most intriguing observation is that the homologues to 
37LRP/67LR can be found in all five kingdoms (archeabacteria, eubacteria, fungi, 
plants animals) and are likely to be present in all organisms (Nelson et al., 2008). 
Phylogenetic analysis of the 37/67 LR sequence suggested that the acquisition of 
the laminin-binding capability by the 37LRP gene product is linked to the 
evolution of the C-terminus, particularly the appearance of the palindromic 
sequence LMWWML. Interestingly, phylogenetic analysis carried out on 37LRP 
gene from different species indicated that all of these proteic sequences are derived 
from orthologous gene, and that 67LR was originally a ribosomal protein 
"37LRP/p40", an acidic ribosomal protein of molecular mass approx. 40 kDa wich 
acquired the additional novel function of a laminin receptor through evolution 
(Deminova et al., 1996; Ford et al., 1999). In 1992, Auth and Brawerman 
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demonstrated that the 37LRP/p40 protein is the murine equivalent of human 
37LRP. More evidences suggest that the 37LRP/p40 protein is a component of the 
translational machinery (Auth and Brawerman 1992). They show that 37LRP/p40 
is part of a cytoplasmic structure that is involved in the translation process.  
The identified binding epitopes for laminin-1 are residues 161–180, referred to as 
Peptide G, (Castronovo et al., 1991), residues 205 and 220, called as the direct 
binding region, and the TEDWS-containing C-terminal repeats (Landowski et al., 
1995). The palindromic sequence LMWWML (a.a. 173-178) within Peptide G has 
been suggested to be the minimal sequence responsible for laminin binding, the 
two consecutive tryptophan (W) residues are impotant for protein to protein 
interaction. Other laminin binding sites have mapped on laminin receptor, and are 
the residues Phe32, Glu35, and Arg155 (Jamieson et al., 2011). Laminin receptor 
are seemingly capaple of binding heparan sulfate (HS) and laminin-1 
simultaneously (Guo et al., 1999; Kazmin et al., 2000; Zidane 2013).  HS binding 
may act as a laminin binding stabilization. Moreover, 37LRP/67LR is a high 
affinity receptor not only for laminin-1 but also for the cellular and infectious 
prion proteins (PrPC and PrPSc, respectively) and plays an important role in prion 
diseases. 
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Figure 3. Main functional regions and binding sites of 37/67 kDaLR. Laminin receptor interacts 
directly with laminin, and at least three regions of the C-terminal domain of the receptor are thought to be 
involved: (i) the most C-terminal 53 amino acids containing four acidic TEDWS repeats; (ii) a putative 
helical stretch between amino acids 205–229; and (iii) a heparan-sulfate-dependent laminin-binding region 
from 161–180. PrP binds the direct binding site, making contact with residues 161–179 of 37/67 kDa LR. It is 
of interest to note that the same region (161–180) of 37LRP corresponds to one (of three) laminin-binding 
sites, which is known as the peptide G region. The second PrP site is an indirect interaction site and is 
mediated by the presence of HSPGs. This indirect binding site maps to amino acids 53–93 on PrP, and either 
101–160 or 180–295 of laminin receptor (modified by Nelson et al., 2008). 
 
 
2.2) 37LRP/67LR cancer and neurodegenerative disease 
As a transmembrane receptor, 37/67 kDa LR serves several functions such as cell 
migration, cell-matrix adhesion, cell viability proliferation and angiogenesis 
(Montuori et al., 1996; Ardini et al., 2002; Berno et al., 2005). However, 37/67 
kDa LR has been shown to be involved in the mobilization of HSCs (haemopoietic 
stem cells) by granulocyte-colony-stimulating factor, and the expression levels of 
37/67 kDa LR positively correlate with mobilization efficiency of HSCs. HSC 
cells stimulate angiogenesis and are thought to give rise to new endothelial cells. 
Interestingly, 37LRP/67LR is involved in the regulation of cell proliferation and 
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survival. Indeed, reduction of its expression results in apoptosis; on the contrary, 
the 37/67 kDa LR dependent cell signaling pathways are important for cell 
survival (Selleri et al., 2006). The receptor is identified as an interacting partner of 
PED/PEA-15 (phosphoprotein enriched in diabetes/phosphoprotein enriched in 
astrocytes), an anti-apoptotic protein whose expression is increased in several 
human cancers, enabling cell proliferation and resistance to apoptosis (Montuori et 
al.  2011; Formisano et al., 2012; Khumalo et al., 2015). A strong correlation has 
also been established between 37/67 kDa LR and cancer angiogenesis; indeed, the 
high expression of this protein correlates with the increase of tumor angiogenesis 
(Stitt et al., 1998; Khusal et al., 2013). Recently, it has been described that the 
37/67 kDa LR specific antibody, W3, blocked cancer angiogenesis (Zuber et al., 
2012). The role of the laminin receptor in cancer progression has been a topic of 
great interest for many years and has therefore been extensively investigated. 
Given that 37/67 kDa LR is involved in a number of cellular processes and is 
found in numerous cellular locations (the cell surface, the cytoplasm, the 
perinuclear compartment and the nucleus), additional roles of this receptor in 
cancer progression have been suggested. Many results show that a number of 
cancer types, such as gastric, colon, colorectal, cervical, breast, lung, ovarian, 
pancreatic and prostate cancers, reveal an overexpression of the 37/67 kDa LR on 
their cell surface; the use of anti-LRP/LR specific antibodies significantly hampers 
the two key steps of metastasis, adhesion and invasion (Menard et al., 1998; 
Montuori et al., 1999; Zuber et al., 2008). Taken together, many results strongly 
suggest that the 37/67 kDa LR laminin-1 interaction in tumor cells enhances the 
proteolytic cleavage of the basement membrane, thus facilitating invasion and 
migration.  
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 Laminin receptor could be implicated in neurodegenerative disease also, such as  
Alzheimer’s disease (AD). AD is the most prevalent form of dementia; the 
accumulation of the amyloid beta (Aβ) peptide is largely considered the primary 
disease causing agent in Alzheimer’s disease, it is generated through the sequential 
proteolytic cleavage of the Amyloid Precursor Protein (APP) by β and γ 
secretases. The amyloid beta (Aβ) shares the same binding partners and a common 
cellular location of 37/67 kDa LR, thus it has been proposed an involvement of the 
37/67 kDa LR receptor in the pathogenesis of Alzheimer’s disease (AD).  show 
that 37/67 Jovanovic et al., 2013 kDa LR can bind and can co-localize with the 
AD relevant proteins APP, β and γ-secretase, respectively, revealing a role for 
37/67 kDa LR in the regulation of APP processing. Moreover, its modulation 
could affect Aβ cytotoxicity and its release from cells (Javanovic et al., 2013; 
Pinnock et al., 2015). 
 
 
2.3) The 37/67 kDa LR as the receptor for PrPc and PrpSc 
 
In a yeast two-hybrid screen technology in Saccharomyces cerevisiae, the 37 kDa 
laminin receptor precursor (LRP) was identified as an interactor for the prion 
protein (Rieger et al., 1997). Further in vitro studies on neuronal and non-neuronal 
cells proved that both the 37 kDa LRP and the 67 kDa high affinity laminin 
receptor act as the receptor for the cellular prion protein (Gauczynski et al., 2001; 
Sarnataro et al., 2016). Mapping analysis of the LRP-PrP interaction site in S. 
cerevisiae revealed that PrP and laminin share the same binding domain (amino 
acids 161 to 180) on LRP. The PrPC binds to 37LRP/67LR kDa via two domains, 
termed PrPLRPd1(aa 144-179) and PrPLRPd2(aa 53-93).  
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The frist one binds directly to LRP/LR whereas the second one depends on the 
presence of heparan sulphate proteoglycanes (HSPGs) on the cell surface. 
Moreover, the aa 161-179 of LRP/LR directly bind PrPC (PrPLRPd1). The indirect 
HSPG-dependent binding domain might be located between aa 101-160 or 
between aa 180-259 of laminin receptor (Hundt et al.; 2001). 
How prions are introduced into the cells is still debated. Although an important 
role has been proposed for the 37 kDa/67 kDa laminin receptor in prions 
internalization.  
Indeed, we have recently demonstrated (Sarnataro et al., 2016) that37/67kDa LR 
and PrPC co-immunoprecipited in neuronal cells also. Moreover, 37 ⁄67 kDa LR 
are involved in the internalization, accumulation and propagation of abnormal 
PrPSc in scrapie-infected neuronal cells in vitro (Gauczynski et al., 2001; Leucht et 
al., 2003) and, 37 ⁄ 67 kDa LR expression levels are greatly increased in the brain, 
spleen and pancreas of scrapie infected rodents (Rieger et al., 1997). 
As accumulation of bovine PrPSc in Peyer’s patches after oral infection in animal 
models has been found this implies that prions cross the intestinal epithelial 
barrier. However, the mechanisms that lead to the internalization of prion particles 
in human intestinal cells after the oral ingestion of bovine prion-infected tissues, it 
is still under investigation. The M cells, present in the covering epithelium of 
Peyer’s patches, has a high phagocytosic activity and are involved in the uptake of 
prions (Da Costa Dias et al.; 2011). Previous results obtained in neonatal mice and 
in primates have described the presence of PrPSc in enterocytes after oral exposure 
to prion strains (Morel et al., 2005). Enterocytes are the major cell population of 
the intestinal epithelium, even at the level of Peyer’s patches, and are known to 
actively participate in endocytosis of nutrients, macromolecules, or pathogens 
through their polarized traffic equipment. Human enterocytes express both PrPC 
and the 37 /67 kDa LR in their apical brush border.  
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Morel et.al; 2005 demonstrated the specificity of bovine prion uptake in human 
enterocytes using the human Caco-2/TC7 cells, which have most of the 
morphological and functional characteristics of normal human enterocytes. Bovine 
prion is rapidly endocytosed through the 37 /67 kDa laminin receptor and 
trafficked toward early endosomes (Morel et al.; 2005). 
 
 
Figure 4. Model for the function of 37/67 kDa LR (LRP/LR) as the receptor for PrP. The PrP 
molecule binds to LRP/LR via PrPLRPbd1 and PrPLRPbd2. PrPLRPbd2 (aa53-93) is dependent on 
the presence of the heparan sulfate arm of a HSPG molecule whereas PrPLRPbd1 (aa 144-179) 
interact directly with LRP/LR. The simultaneous presence of both PrPLRPbd1 and PrPLRPbd2 
would stabilize the binding of PrP and laminin receptor. Direct binding of 37/67kDa LR to PrP 
occurs via the direct binding site located between aa 169-179 of LRP/LR. The indirect HSPG 
dependent binding domain might locate between aa 205-229 (modified by Gauczynski et al., 2001). 
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2.4) Molecular strategy to inhibit 37/67 kDa lamini receptor  
 
The importance of the receptor in the PrPSc propagation is confirmed by several 
studies in which laminin receptor downregulation is able to reduce the PrPSc 
formation in scrapie-infected neuronal cells (Vana and Weiss, 2006).  Thereupon 
several approaches regarding prion diseases targeting 37/67 kDa LR have been 
developed (Castronovo et al.,1991; Gauczynski et al., 2001; Khumalo et al., 2015) 
including i) anti-37/67 kDa LR antibodies (Chiesa et al., 2009), ii) polysulfate 
glycans (Prusiner et al., 1998) and iii) small interfering RNAs directed against the 
LRP m RNA (McKinley et al., 1991). As anti-37/67 kDa LR antibody, it has been 
used the polyclonal antibody (W3). It has shown curative effect on scrapie infected 
N2a cells (Leucht et al., 2003). This antibody a) prevents the binding of infectious 
prions to mammalian cells (Gauczynski et al., 2006) and b) blocks endocytosis of 
PrP BSE by enterocytes (Morel et al., 2005). Since a polyclonal antibody format is 
not suitable for a therapy in animals or humans, single-chain antibodies directed 
against 37/67 kDa have been developed. Different studies characterized two single 
chain antibodies (scFvs) N3 and S18 that are directed against 37/67 kDa LR. The 
single chain antibody S18 shows inhibitory effects on prion replication in vivo, 
indeed, peripheral prion propagation levels are reduced. However, the S18 
mediated reduction of the peripheral PrPSc propagation was not concomitant with a 
significant prolongation of the incubation and survival times in scrapie infected 
mice treated with scFv S18. One reason for that might be the short half-life of the 
antibody, approx. 12 h in the blood of animals (Zuber et al.; 2008).  
As polysulfated Glycanes can be a molecular target to inhibit infections prions, 
Gauczynski et al; 2006 have shown that Heparan sulfate mimetics (HMs), which 
represent dextran-based molecules (chemically substituted with defined amounts 
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of carboxymethyl, hydrophobic benzylamide, and sulfated groups) inhibit PrPSc 
synthesis in infected neuronal cells and impair the endocytosis of prion rods. It 
was suggested that the HM molecules might act by directly interfering with the 
PrPC/PrPSc conversion process. One of the mechanisms suggested claims that the 
Heparan sulfate mimetics block PrPSc binding to the cells by competing with the 
binding to heparan sulfate and to LRP/LR (Gauczynski et al.; 2006).  
However, anti-TSE strategies targeting PrP and laminin receptor have been 
contested, since the molecules injected into the brain of mice led to rapid neuronal 
apoptosis (Solforosi et al., 2004). Other compounds are highly toxic and lacks of 
the permeability across the blood-brain barrier. This prompted us to test the effect 
of a specific 37/67 kDa LR small organic inhibitor NSC47924 on prion protein 
biology of prions. 
 
 
3. Biological properties of the PrP-like protein Shadoo  
3.1) Looking into Prnp and Sprn genes: Structural homology and diversity 
The SPRN gene, located on chromosome 7 in mice and 10 in humans, encodes 
Shadoo (Sho), a N-glycosylated glycophosphatidylinositol-anchored (GPI) protein 
that shows neuroprotective properties. Shadoo is the third member of mammalian 
prion protein family, which includes prion protein (PrP), encoded from Prnp gene, 
and Doppel, a testis-specific protein involved in the male reproductive system, 
encoded from Prnd. The Prnp gene is located on chromosome 2 in mice  and 20 
humans. It consists of three exons with the entire open reading frame located in 
exon 3. Like Prnp, the entire open reading frame of Sprn is contained within a 
single exon. Sprn gene was discovered in a public domain database for nucleotide 
sequences, showing some similarities to the Prnp sequence.  
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Thus, it was revealed that Sprn could encode a short protein resembling the 
flexibly disordered N-terminal part of the PrP: in particular, the alanine- and 
valine-rich central hydrophobic region. The protein was named Shadoo (Shadow 
of Prion Protein) and was discovered in silico by Premzl et al. in 2003. After an 
NMR study and circular dichroism analyses (Premzl et al., 2003; Watts et al., 
2007), they defined Shadoo as a natively unstructured protein. Sprn gene seems to 
be present in the genomes of lower organisms, such as zebrafish, all the way up to 
rodents and primates (Premzl et al., 2003).  
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3.2) Proteic structure of Prion and prion-like protein Shadoo  
 
PrPC is synthesized with N- and C- terminal signal sequences; the N-signal peptide 
targets it to the endoplasmic reticulum (ER), but not very efficiently, because 
small amounts of cytoplasmic PrP are generated. In the ER, first PrP N-signal 
peptide and  C-terminal signal peptide are removed, followed by the addition of a 
GPI anchor, which tethers PrPC to the outer leaflet of the plasma membrane 
(Harris et al., 1999). As a GPI-anchored protein, PrPC is found in cholesterol-rich 
lipid raft domains within the membrane. The overall architecture of Shadoo recalls 
the N-terminal half of PrPC, although Shadoo lacks the octarepeat sequences found 
in PrPC. In particular, there are several features which are present in both Shadoo's 
and PrP's natively unstructured N-terminus: i) tandem positively charged RRG 
boxes (rich in glycine, serine, alanine and arginine; aa.26 to 48 aa), predicted to 
bind RNA (Lau et al., 2012); ii) HD (hydrophobic tract, from aa63 to aa 82); iii) 
N-linked glycosylation, but in Shadoo it is predicted to occur at a single site; iv) C- 
terminal attachment signal for the GPI anchor. Shadoo appears to lack any 
discernible elements of secondary structure, in concordance with its homology to 
the unstructured N-terminus of PrPC (Watts et al., 2007; Daude and Westaway et 
al., 2011); (see Figure 5). This could be explained by the fact that: i) the Shadoo 
region analogous to the α-helical domain present in PrPC is not long enough to 
accommodate three α-helices; ii) Shadoo misses cysteine residues, preventing the 
formation of stabilizing disulfide bridges (Daude et al., 2010).  
More recently, it has been demonstrated that ER signal peptide of Shadoo has the 
property to mediate an alternative targeting to mitochondria. The targeting 
direction of this signal peptide is determined by intrinsically disorder elements 
within the nascent chain. (Pfeiffer et al., 2013) Loss of the pro-α-helical domains 
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and/or deletion of the C-terminal GPI signal sequence promote Shadoo 
translocation into mitochondria. In addition, the finding that a C-terminal GPI-
anchor signal sequence is sufficient to promote efficient ER import of Shadoo 
indicates that the nascent chain remains translocation competent until the complete 
protein is synthesized. On the other hand, proteins containing structured domains 
are efficiently imported into ER  
 
 
Figure. 5 Domain structures of PrPC and Shadoo Proteins. The schematic in PrPC includes 
octarepeats, hydrophobic region (‘HD’); a, alpha helices; b strands (‘b’) and N-glycosylation sites 
(CHO). For Shadoo the basic repeats, HD and single N-glycosylation site are shown. Diagonal 
slashes adjacent to GPI attachments sites of PrPC and Shadoo indicate the existence of an 
endoproteolysis site(s) that result(s) in secreted forms of the respective proteins (modified by Watts 
et al., 2010). 
 
 
3.3) Endoproteolitic processing of prion protein family 
 
A feature of the prion glycoprotein family is their endoproteolitic processing. 
Endoproteolysis of prion protein probably plays a fundamental role in PrPSc 
propagation, because the predominant C-terminal fragment switches from C1 to 
C2 fragments during disease progression. Under healthy conditions, a-cleavage of 
PrPC is abundant, and generates a 17- kDa C-terminal fragment, named ‘C1’.  
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This fragments are generated by a cleavage that disrupts the neurotoxic and 
amyloidogenic region of PrPC, immediately preceding the hydrophobic domain, 
whose residues are 106-126. During disease, α-cleavage occurs less frequently 
than β-cleavage after the octarepeat region, thus making the ‘C2’ fragment 
dominant. The 106-126 residues remain intact in C2, suggesting a role for C2 
in prion diseases.  
Incomplete descriptions of cleavage products for Shadoo have been reported but 
their characterization could be promising for knowledge of the biological 
significance of PrPC. In fact, some studies have indicated that the N-terminal 
domain of PrPC can be replaced by that of Shadoo and maintains its ability to 
protect cells from stress-induced toxicity, thus indicating that Shadoo and PrPC are 
involved in similar signalling pathways. Cleavage of Shadoo generates fragments 
that possess overlapping functions with those of PrPC and involves the generation 
of the C2 fragment, that is generated together with the C1 Shadoo fragments by a 
common mechanism (for example a hypothetically C1 protease that may cut 
inefficiently at the adjacent C2 site); (Mays et al., 2014). However, Shadoo 
fragments biological function remain largely unknown. 
 
3.4) Shadoo expression and its relationship with PrPC 
 
Expression of Shadoo in the mouse brain is less widespread than PrPC. Shadoo is 
most readily apparent in the hippocampus and it is found in the cell body in some 
neurons of the lateral hypothalamus. Then it is prominent in two regions in which 
PrPC is notably absent: the Purkinje cells in the cerebellum and the dendritic 
processes of hippocampal pyramidal cells. Moreover, the physiological function of 
Shadoo in CNS is unknown and evaluating Sprn knockout mice may help to 
clarify its role.  
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Recent studies report that Sprn0/0 animals don’t have malformation at birth or in 
adult life. On the other hand, Prnp 0/0 mice is not lethal and lack a strong 
phenotype in the mammals (Beuler et al., 1992; Manson et al., 1994), despite its 
early embryonic expression; moreover, Prnp lack induced embryonic lethality in 
Zebrafish, arguing for the involvement of the Prion protein family in embryonic 
development. Whereby, in the mammals, another protein takes over PrPC function 
in knockout mice; Shadoo, which shares some spatial regulation and properties 
with PrPC, appears to be a good candidate for being this hypothetical, host-
encoded PrP-like protein. Interestingly, a lethal embrionic phenotype was 
described in Prnp 0/0 mice and Sprn knockdown. The PrnpKOSprnKD embryos 
suffer from a neural defect with a failure of closure of the cranial tube. However, it 
is commonly accepted that such a default could not explain the observed lethality, 
but a developmental defects of trophoblastic lineage was sufficient to explain the  
observed lethal phenotype (Young et al., 2009; Passet et al., 2012). Other studies 
have reported that Prnp and Sprn KO mice did not produce embryonic lethality 
(Daude et al., 2012). Three hypotheses were proposed that could conciliate this 
discrepancy in phenotype: i) the use of similar but not identical genetic 
backgrounds, ii) an adaptation of the Sprn-knockout embryos to the lack of this 
protein and iii) an alteration of the Sprn-overlapping Mtg1 transcript expression 
level by the shRNA.  
Similar to PrP, recombinant mouse and sheep Shadoo proteins are able to form 
amyloid assemblies under native condition (Daude et al., 2010). Shadoo HD 
region seem to have self-assembly properties (Rambold et al. 2008) and the ability 
to form amyloid. The conformational and assembly properties of this HD region 
seems to dictate important biological activities.  
An intriguing aspect of Shadoo biology is its prion-disease specific 
downregulation (Westaway et al., 2011).  
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However, the mechanism governing the loss of Shadoo protein during disease 
remains to be determined. 
Recently, it has been shown that Shadoo levels are reduced in the brains of mice 
infected with the RML strain of prions, in the brains of prion-infected rodents and 
sheeps (Watts et al., 2007). Furthermore, nonsense mutations in the SPRN gene 
were found in two patients with variant CJD, but not in control patients. On the 
other hand, Shadoo overexpression did not influence the kinetics of prion 
replication in mice. The quantitative inverse relationship between Shadoo and 
protease-resistant PrPSc levels in the brain, suggests that the relative levels of these 
two proteins are mechanistically linked. Thus, Shadoo may be an indicator of an 
early response to PrPSc accumulation in the central nervous system (CNS) 
hundreds of days prior to the onset of neurological symptoms (Watts et al., 2007). 
Recently it was demonstrated PrPC-Shadoo interaction in a yeast two-hybrid 
system. To examine the regions of PrPC and Shadoo responsible for their 
interaction to each other, a series of deletion mutants were constructed and the 
interactions were assayed. Thus, the interaction site of PrPC is 108–126 and of 
Shadoo, 61–77 (Jiayu et al., 2010). However, the contribution of this interaction to 
the evolution of prion pathology or to the folding pathway of PrPC remains 
uncertain. 
 More recently, Ciric el al, (2015) have described for the first time that Shadoo can 
interfere with the PrP-folding pathway and prion replication process. Using cross-
linking experiments, they showed that full-length PrPC and Shadoo are able to 
form a more stable 1:1 heterocomplex exhibiting quaternary structure different 
from the one formed in the absence of Shadoo. However, Shadoo also 
cooperatively interacts with C-terminal C1 fragment of PrPC, derived from 
physiological PrPC proteolytic processing.  
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Indeed, C1 fragment has been reported to act as a dominant–negative inhibitor of 
PrPSc formation (Westergard et al., 2011). The cooperative binding of Shadoo to 
the C1 fragment traps the fragment and thus interferes with its dominant negative 
inhibitor property, which could enhance the PrPSc replication process. The dual 
binding behaviour of Shadoo may thus confer regulatory properties on the prion 
conversion process (Figure 6). 
 
 
 
 
 
 
Figure 6. Proposed modes of Shadoo (Sho) action on the conversion of PrPC to PrPSc. (a) 
PrP truncated form C1 has been reported to act as dominant-negative inhibitor of PrP conversion. 
(b) By directly interacting with full-length PrP, Sho modifies the PrP-folding pathway and thereby 
enhances the conversion rate (c) An allosteric interaction between Sho and PrP truncated form C1 
traps C1in a multimeric complex, switching off the dominant-negative inhibition of C1 
and thus enhancing the conversion process (modified by Ciric et al., 2015). 
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Aims of the study 
 
Prion diseases lack effective therapeutic treatment to date; they are caused by the 
conversion of the cellular prion protein (PrPC) into the disease-associated form 
PrPSC, which is the aggregated, misfolded isoform of PrPC, which accumulates in 
the central nervous system. However, it is not yet understood how the misfolding 
of prion protein induces neurodegeneretion. It has been demonstrated by in vitro 
and ex-vivo experiments that prion propagation requires the presence of the non-
integrin laminin receptor (Leucht et al., 2003), implicating that the approaches 
which downregulate 37/67kDa LR are promising alternative strategies for the 
treatment of prion diseases.  
Since PrPC shows a number of binding partners, it is important to evaluate the role 
of the other genes and proteins in prion diseases, as well. 
Recently, it has been observed that the infected scrapie brain presented a reduction 
of Shadoo protein levels (Daude et al., 2010). Moreover, intriguing aspect of 
Shadoo biology is its natural tendency to convert to amyloid-like forms in vitro 
(Daude et al., 2010) and its capability to act as an holdase on PrPC folding .This 
feature could represent a functional link between PrPC and Shadoo in the 
conversion of PrPC to its misfolded isoform (PrPSc).  
 
My PhD work has been focused on two major projects:  
 PROJECT 1: The effects of 37/67 laminin receptor (LR) inhibitor, 
NSC47924, on LR cellular localization and on its interaction with the 
cellular prion protein 
 PROJECT 2: Role of lipid rafts and proteasome in the acquisition of 
“scrapie-like” properties of PrP-like protein Shadoo in neuronal cells 
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Reagents and antibodies 
Cell culture reagents were purchased from Sigma-Aldrich Laboratories (St Louis, 
MO) . The SAF32 and SAF61 antibodies (directed, respectively, against the N- 
and C-terminal domain of PrPC) were from Bertin Pharma-Bioreagent Department 
(France). The anti- KDEL, anti-CNX, anti-CLR, anti-Golgin, anti-EEA1 and anti-
ERp57 antibodies were from StressGen Biotechnologies Corp (Victoria, BC, 
Canada). Anti-Lamp1 antibody was from BD Pharmigen and anti-b-tubulin 
antibody was from Abcam. SPRN (R-12) sc-136909 Shadoo-Antibody, TRAP1 
sc-13557, Bip/Grp78 (sc-1051), F1atpase, ATP5B subunit, sc-58619, anti-GAPDH  
(sc-69778) from Santa Cruz Biotechnology. Anti-Transferrin Alexa-488-
conjugated (Tfr488), Alexa-488-, Alexa-546-conjugated secondary Abs and 
Lysotracker Red DND-99 were from Invitrogen (Molecular Probes). DRAQ5 and 
DAPI dyes were purchased from Cell Signal Technology. Protein-A-Sepharose 
was from Sigma. Biotin-LC was from Pierce and all other reagents were obtained 
from Sigma Chemical Co. (St Louis, MO. Production of recombinant and anti-
67LR antibodies: a recombinant His-tagged 37LRP polypeptide (r37LRP) was 
made in bacteria and Nickel affinity purified, as described (Pesapane et al., 2015; 
Jovanovic at al., 2015). (Human) Recombinant PrP (PO2) was from Abnova 
(Taipei, Taiwan). The polyclonal 5004 Ab able to recognize both the 37 kDa and 
the 67 kDa forms of LR is used in the immunofluorescence, Western blot analysis 
and immunoprecipitation was performed using the polyclonal 4290 Ab was made 
against a C-terminal peptide derived from LR and was a kind gift from Dr. Mark 
E. Sobel (Bethesda, MD); the NSC47924 inhibitor has been already described 
(Pesapane et al., 2015). ALLN was from Calbiochem (La Jolla, CA), Methyl-β-
cyclodestrin (βCD) from Sigma Chemical Co. (St Louis, MO). 
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Cell culture and drug treatment 
GT1 (hypothalamic neuronal mouse cell line) and HEK-293-LR (HEK-293 stable 
expressing T7/His-tagged 37LRP; Pesapane, et al., 2015)  were grown in 
Dulbecco’s modified Eagle’s medium (DMEM), with 4500 mg/glucose/L, 110 mg 
sodium pyruvate and L-glutamine (SIGMA D6429), supplemented with 10% fetal 
bovine serum. SHSY5Y (derived from human neuroblastoma), were grown in 
RPMI-1640 (Euroclone), with 4500 mg/glucose/L, 110 mg sodium pyruvate and 
L-glutamine (SIGMA D6429), supplemented with 10% fetal bovine serum. Cells 
were cultured at 37°C under 5% CO2.  For inhibitor NSC47924 treatment, the 
cells were washed in serum free medium, incubated for 30 min at room 
temperature (RT) in Areal medium (13.5 g/l of Dulbecco’s modified eagle’s 
medium with glutamine without NaHCO3 (SIGMA-D-7777), 0.2% BSA and 
20mM HEPES, final pH 7.5) and for further indicated times at 37 °C under 5% 
CO2 in the presence of 20 μM inhibitor in DMEM supplemented with 1% serum. 
NH4Cl (20 mM in culture medium) was used to inhibit endo/lysosomal protein 
degradation for 2 days. Proteasomal block was performed with 150 μM ALLN for 
7 hours in complete medium. Methyl-β-cyclodextrin (βCD) treatment was carried 
out as described elsewhere (Keller and Simons, 1998). Briefly, GT1 cells were 
plated on dishes and βCD (10 mM) was added to the Areal-medium containing 1 h 
at 37°C to cells. 
 
Indirect immunofluorescence and confocal microscopy 
To analyze protein steady-state localization, GT1 cells were cultured to 50–70% 
confluence in growth medium for three days on coverslips, washed in PBS, fixed 
in 4% paraformaldehyde (PFA), permeabilized or not with 0.2% TX-100 for 5 min 
(where indicated) and processed for indirect immunofluorescence using specific 
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antibodies 1 hours in PBS/BSA 0.2%. The cells were incubated with anti-PrP 
SAF32 (IgG2) monoclonal antibody (2 mg/ml, 1:100) and anti-37/67kDa LR 
rabbit 5004 policlonal antibody (1 mg/ml, 1:50) to label PrPC and 37kDa/67kDa 
LR, followed by incubation with fluorophore-conjugated secondary antibodies. 
For lysosome and mitochondria staining, cells were incubated for 1 hr with 
Lysotracker (1:1000) and 1 hr with Mitochondria (1:1000) respectively in 
complete medium before fixing. Where indicated, anti-Lamp1 antibody was used 
as marker of endo-lysosmal compartment. For Tfr-Alexa 488 staining, the cells 
were incubated 45 min in complete medium before proceeding with 
immunofluorescence. Nuclei were stained by using DRAQ5 dye (1:5000) or DAPI 
(1:1000) in PBS.  
To analyze cell surface localization of 37/67kDa LR and PrPC, the cells were first 
incubated (or not, control) with the inhibitor for the indicated times and then fixed 
in PFA 4% and processed for immunofluorescence under non permeabilized 
conditions by labelling laminin receptor and PrPC with the specific antibodies.  
Internalization assay. In order to exclusively label the cell surface 37/67kDa LR 
and PrPC protein pools and to follow their fate from the cell surface, GT1 cells 
grown on coverslips were first incubated (pulse) with 5004 and SAF32 primary 
antibodies for 30 min at 4 °C (which blocks membrane trafficking events; 
Arancibia-Cárcamo et al., 2006). Primary antibodies were diluted in Areal 
Medium. The cells were then washed to eliminate excess of unbound antibodies 
and then shifted at 37 °C under 5% CO2, to allow endocytic processes, for 
indicated times (chase) in the presence or not of 20 mM NSC47924 in the culture 
medium. GT1 cells were fixed and permeabilized before incubation with 
fluorescently-conjugated secondary antibodies and laser scanning confocal 
analyses (Sarnataro et al., 2009). 
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Pearson’s correlation coefficient (PCC) was employed to quantify colocalization 
(Bolte et al., 2006) between 37/67kDa LR and PrPC (as well as other intracellular 
markers), and was determined in at least 25 cells from four different experiments. 
PCC was calculated in regions of 37/67kDa LR and reference protein co-presence 
(Bolte et al., 2006). In brief, the Otsu algorithm was applied to segment laminin 
receptor and PrPC (as well as other intracellular markers) images, in order to define 
co-localization regions of the reference proteins. The PCC was then calculated in 
the defined regions for the images of interest. Whereas PCC provides an effective 
statistic for measuring overall association of two probes in an image, it has the 
major shortcoming that it indirectly measures the quantity of one protein that 
colocalizes with a second protein (Dunn et al., 2011). This quantity can be 
measured via Manders' Colocalization Coefficient (MCC). The degree of 
colocalization between 37/67kDa LR and PrPC was quantified using the 
colocalization finder and JaCoP plug-in of ImageJ software 
(http://rsb.info.nih.gov/ij/). MCCs were measured for at least 25 cells per sample. 
Immunofluorescences were analysed by the confocal microscope Zeiss META 510 
equipped with an oil immersion 63x 1.4 NA Plan Apochromat objective, and a 
pinhole size of one airy unit. We collected twelve-bit confocal image stacks of 10-
15 slices at 0.4µm Z-step sizes from dual- or triple-labeled cells using the 
following settings: green channel for detecting Alexa-488, excitation 488 nm 
Argon laser, emission bandpass filter 505–550 nm; red channel for detecting 
Alexa-546, excitation 543 nm Helium/Neon laser, emission bandpass filter 560–
700 nm (by using the meta monochromator); blue channel for detecting DAPI, 
excitation 405 nm blue diode laser, and emission bandpass 420–480 nm; blue 
channel for detecting DRAQ5, excitation 633 nm Helium/Neon laser.  
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Measurements of fluorescence intensity were taken on a minimum of three 
confocal stacks per condition, from a single experiment (∼84 cells), using LSM 
510 Zeiss software. The background values raised by fluorescent secondary 
antibodies alone, were subtracted from all samples. 
Shadoo indirect immunofluorescence: GT1 cells were grown for 3 days on 
coverslips, washed with PBS, fixed and processed for indirect 
immunofluorescence (the cells were permeabilized with methanol/acetone 1:1) 
using anti-Sho R12 pAb and anti-PrPC SAF32 mAb. Sho and PrPC were visualized 
with Alexafluor-546 or 488-conjugated secondary antibody, respectively. Images 
were acquired by a Leica SP5 TCS SMD confocal microscope by using a 63x oil 
immersion objective, a 488 nm Argon laser for AlexaFluor-488 conjugated 
secondary antibodies (green channel), a 561 nm laser for AlexaFluor-546 
conjugated secondary antibodies (red channel); 633 nm laser for DRAQ5 (nuclei, 
blue channel). Pearson Correlation Coefficient (PCC) was employed to quantify 
colocalization (Bolte and Cordelières, 2006). 
Immunoprecipitation/Co-immunoprecipitation 
To immunoprecipitate PrPC or 37/67kDa LR, the cells were grown in 100 mm 
dishes, washed three times with cold PBS and lysed on ice for 20 min in lysis 
buffer 1 (25mM Tris-HCl pH 7.5, 150 mM NaCl, 5mM EDTA, 1% TX-100) with 
protease inhibitor mixture (leupeptin, antipain, pepstatin, and 1 mM 
phenylmethylsulfonyl fluoride). The samples were quantified with Bradford assay 
with Bio-Rad Protein Assay Dye Reagent Concentrate, diluited 1:5 in water; 1.2 
mg of proteins were immunoprecipitated, while 80 mg of proteins were kept for 
totals. Lysates were pre-cleared with protein-A sepharose beads (5 mg/sample) for 
30 min at 4°C and incubated overnight with 1µg/ml SAF32 or SAF61 anti-PrP 
antibodies, or with a polyclonal anti-LR 4290 antibody (2µg/sample) to 
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immunoprecipitate 37/67kDa LR (both coupled with Protein-A sepharose); 
(Campana et al., 2007). Pellets were washed three times with cold-lysis buffer 1, 
then boiled with SDS sample buffer 2X (Tris 1M pH 6.8, SDS 10% , glycerol 20% 
and bromophenole blue and 10% b-mercaptoethanol), loaded on 12% 
polyacrylamide gels (30% ACRYL/BIS SOL 37.5:1), and revealed by Western 
blotting with 4290 and/or SAF32 Abs followed by ECL detection (Pierce 
Euroclone). Densitometric analysis was performed using the free image-
processing software ImageJ.  
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Immunoprecipitation of Molecular Chaperones 
To immunoprecipitate Calreticulin (CLR) the cells were grown in 100 mm dishes, 
washed three times with cold PBS and lysed JS buffer (1% TX-100, 150m M 
NaCl, 1% Glycerol, 50 mM HEPES, p H 7.5, 1.5 mM MgCl2, 5 mM EGTA) with 
protease inhibitor coktail, for 20 min on ice, screped and microfuge tubes. The 
lysates were then precleared with protein A-Sepharose beads (5 mg/sample) for 30 
min and incubated overnight at 4°C with CLR. The pellets were washed twice 
with cold lysis buffer and three times with PBS. The samples were then boiled 
with SDS-sample buffer (Sarnataro et al., 2004). TRAP-1 immunoprecipitation 
was carried out on 1,5 mg of total extracts. Cells were lysed in cold lysis buffer 
[20 mm Tris (pH 7.5) 60 mm KCl, 15 mm NaCl, 2 mm EDTA, 1% (vol/vol) 
Triton X-100, 1 mm phenylmethylsulfonyl fluoride, 2 mg/ml aprotinin, 2 mg/ml 
leupeptin. Protein concentration was quantified using the Bio-Rad protein assay kit 
(Bio-Rad Laboratories)Lysates were incubated O/N  with 50 µl( 1mg/ml) protein 
Protein A/G magnetic beads (Bio-Rad) and TRAP-1 (1µg/ml) antobody. Negative 
control experiments were performed by adding magnetic beads and IgM to the 
cleared lysate. Then, the Co-IP was washed with PBS-T (PBS + 0.1% Tween 20), 
beads were magnetized and supernatant were discarded. Pellets were boiled with 
SDS sample buffer 2X at 95°C. The samples were loaded on 14% polyacrylamide 
gels and revealed by Western blotting against Shadoo, CLR and TRAP-1. 
 
Biotinylation assay 
GT1 cells grown on dishes were cooled on ice and biotinylated with NHS-LC-
Biotin at 4°C (Zurzolo et al., 1994). Cells were lysed for 20 min using buffer 1 
(25mM Tris-HCl (pH 7.5), 150 mM NaCl, 5mM EDTA, 1% TX-100). 
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Biotinylated cell surface proteins were immunoprecipitated with streptavidin beads 
(40 ml/sample, Pierce n. 20349). 37/67kDa LR was specifically immunorevealed 
with the 4290 pAb and PrPC with SAF32 mAb. In the case of NSC47924 
treatment, the cells were first incubated with the inhibitor (or not, control) for 
indicated different times and then, biotinylated on ice, following the protocol 
described above.  
Steady-state plasma membrane distribution: 80% confluent cell layers on plates 
were biotinylated and processed for immunoprecipitation with streptavidin beads 
(biotinylated material, cell surface), as previously described (Sarnataro et al., 
2002). To recover the biotinylated immunoprecipitated Shadoo and PrPC, the 
samples were boiled with Laemmli buffer for 10 min and then loaded on 14% gels. 
After transfer on PVDF by Western blot, total and cell surface Shadoo and PrPC 
were revealed with R-12 and SAF32 antibody, respectively. 
 
Binding of soluble r37LRP to immobilized human recombinant PrP 
High binding plates with 96 flat-bottomed wells (Corning, Amsterdam, ND) were 
coated with 125 ng/well of human recombinant PrP diluted in PBS, or BSA as a 
negative control, and incubated at 4 °C overnight. After a wash in PBS, residual 
binding sites were blocked for 1 h at 37°C with 200 ml of blocking buffer (2% 
FCS, 1 mg/ml BSA, in PBS). Wells were incubated with 2 mg r37LRP (diluted in 
PBS, 1 mg/ml BSA), which contained a 6X-His-tag, alone or in presence of 
NSC47924, for 1 h at 37 °C. Each well was washed three times with wash buffer 
(0.5% Tween in PBS). Penta-His HRP conjugate (1:500) (Qiagen, Hilden, 
Germany) was added for 2 h at room temperature. After washing, substrate 
solution was added and absorbance was detected at 490 nm on an ELISA plate 
50 
 
reader (Bio-Rad). Binding was determined by subtracting background absorbance 
(BSA wells).  
 
Statistical analysis 
Statistical significance of samples against untreated cells was determined by One-
way analysis of Variance (ANOVA), followed by the Dunnett's test. Each value 
represents the mean±SEM of at least three independent experiments performed in 
triplicate (*,§, P< 0.05). 
 
QproteomeTM Mitochondria Isolation  
QproteomeTM Mitochondria Isolation kit from Qiagene (37612) was used to 
purify mitochondria from eukaryotic cells. 6 x 106 SHSY5Y cells were processed. 
The cell suspension was centrifuged at 500 x g for 10 min at 4°C. Supernatant was 
removed and the pellet was washed using 1 ml of 0.9% NaCl solution for two 
times. After washing, cells were suspended with 1 ml of Lysis Buffer (protease 
inhibitor solution was added) which selectively disrupts the plasma membrane 
without solubilizing it, resulting in the isolation of cytosolic proteins. Plasma 
membrane and compartmentalized organelles, such as nuclei, mitochondria, and 
the endoplasmic reticulum (ER), remained intact and were pelleted by 
centrifugation at 1000 x g for 10 min at 4°C. The resulting pellet was resuspended 
in 500 µl of Disruption Buffer, repeatedly passed through a narrow-gauge needle 
(to ensure complete cell disruption), and centrifuged at 1000 x g for 10 min at 4°C.  
The pellet contains nuclei, cell debris, and unbroken cells. The supernatants were 
centrifuged at 6000 x g for 10 min at 4°C. The pellet contains mitochondria. The 
supernatant represents the microsomal fraction.  
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The mitochondrial pellet was washed with 1 ml Mitochondria Storage Buffer and 
then Centrifuged at 6000 x g for 20 min at 4°C. Then the mitochondrial pellet was 
re-suspended with 100 ml of Mitochondria Storage Buffer.  
Each isolated fraction was quantified with Breadford assay with Bio-Rad Protein 
Assay Dye Reagent, diluited 1:5 in water. 15mg of proteins of each fraction (cyt-
ER-Mito) were boiled with SDS-sample buffer 2X, loaded on 14% polyacrylamide 
gel and reveled by western blotting with SPRN-R12 antibody to reveal Shadoo. 
PVDF membranes were probed with GAPH, F1ATPase and BiP, as cytosol, 
mitochondria and ER marker respectively. 
 
TX-100 extraction  
Cells grown in 60-mm dishes were washed twince with PBS containing 1mM 
CaCl2 and 1mM MgCl2 (PBS C/M) and then lysed for 20 min on ice in 1ml 
Extraction Buffer (25 mM Hepes pH 7.5, 150 Mm NaCl, 1% TX-100). Lysates 
were collected and centrifuged at 14000 r.p.m. for 2 min at 40C. Supernatants, 
representing the soluble material, were removed and 1% SDS was added; the 
pellets were then solubilized in 100 µl of Solubilization buffer (50 mM Tris p H 
8.8, 5 mM EDTA, 1% SDS). DNA was sheared through a 22-g needle. The pellets 
were solved, boiled 3 min and 900 µL of Extraction buffer was added. Proteins 
were TCA precipitated from the soluble and insoluble materials and Shadoo was 
revealed by Western blotting with R-12 antibody. 
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Assay for DRM-association 
Sucrose density gradients 
Cells were grown to confluence in 150-mm dishes, washed in PBS Ca++/Mg++ 
and lysed for 20 min in TNE/TX-100 1% on ice (Sarnataro et al., 2002; Broquet et 
al., 2003). Lysates were scraped from dishes and sheared though a 22-g needle and 
then centrifuged at 14.000 rpm 10 min at 4°C. Supernatants were placed at the 
bottom of centrifuge tube, brought to 40% sucrose. A sucrose gradient (5-35% 
TNE) was layered on the top of the lysates and the samples were centrifuged at 
39.000r.p.m. for 18h in an ultracentrifuge (model SW41 Beckman Institute, 
Fullerton, CA, USA). One-milliliter fractions (12 fractions in total) were harvested 
from the top of the gradient. Specifically, starting from the top of the gradient the 
fractions 4-7 (representing DRMs) and 8-12 (non-DRMs) were collected and 
loaded on gel. After transfer on PVDF by Western blot, Shadoo, PrPC and 
Flotillin-2 were revealed by specific antibodies and ECL.  
 
Assays for scrapie properties 
Triton/Doc insolubility: cells were lysed in Triton/Doc buffer (0.5% Triton X-100, 
0.5 Na Deoxicolate, 150 mm NaCl and 100 mm Tris, pH 7.5) for 20 min and 
cleared lysates were centrifuged at 265000×g for 40 min in a TLA 100.3 rotor of 
Beckman Optima TL ultracentrifuge. Shadoo was recovered in the supernatants 
and pelleted by TCA precipitation. It has been shown that in these conditions only 
PrPSc but not PrPC from brain extracts and cell culture lysates (from CHO, NIH 
3T3 or neuroblastoma cells) will sediment (Lehmann and Harris, 1997; Priola and 
Chesebro 1998). 
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Proteinase-K digestion: to measure proteinase K-resistance, lysates were digested 
with proteinase- K (3.3 µg/ml or 20 µg/ml, as indicated) for 2 and 10 min at 37 °C; 
the proteins were TCA precipitated and then analyzed for Shadoo by 
immunoblotting with the specific antibody. The conditions used for proteinase 
digestion are identical to those previously published (Lehmann and Harris, 1997; 
Priola and Chesebro, 1998; Sarnataro et al., 2004) 
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RESULTS AND DISCUSSION 
PROJECT-1 
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Results 
1.1) PrPC and 37/67kDa LR 
expression and intracellular 
localization in both 
neuronal and non-neuronal 
cells 
 
The endogenous laminin receptor 
from neuronal GT1 cell lysates 
migrated on SDS-PAGE as two 
different bands corresponding, 
respectively, to the laminin receptor 
precursor (37kDa LRP) and the 
mature band (presumably the 
acylated isoform or the 
homodimeric/heterodimeric one) as 
shown before (Montuori et Sobel, 
1996). Lysates from HEK-293-LR  
cells stably transfected with a human 
37LRP cDNA were loaded for 
reference (Pesapane et al., 2015) 
(Figure 1a). As already observed 
(Buto et al., 1998), the precursor 
molecule showed an anomalous 
electrophoretic mobility, which 
accounts for an apparent molecular 
mass of ~44 kDa, and as previously 
described by Alqahtani et al., 2014, 
in cells expressing endogenous 
37kDa LRP and 67kDa LR, the latter 
species runs in SDS–PAGE gels with 
an  
apparent molecular mass of ~60 kDa, 
which is lower than might be 
expected of a homodimer of 37kDa 
LRP. The most likely explanation for 
this is that LR is resistant to 
denaturation in SDS, and thus 
maintains a more compact structure 
than during SDS–PAGE and runs 
with a higher electrophoretic 
mobility.  
PrPC was typically glycosylated, 
showing different bands ranging 
from ~27 to ~37 kDa; the 
unglycosylated form which migrates 
at ~27 kDa, the intermediate 
monoglycosylated form, which 
migrates at 28–30 kDa; and the 
highly glycosylated forms which 
migrate as bands spanning 33–37 
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kDa (Zannuso et al.,1998; Sarnataro 
et al., 2004). We next analyzed the 
subcellular localization of both 
laminin receptor and PrPC, by 
indirect immunofluorescence and 
confocal microscopy of neuronal 
GT1 cells grown on coverslips 
(Figure 1b).  
PrPC was found mainly on the cell 
surface and in the Golgi area as 
previously demonstrated in GT1 cells 
and other neuronal cell lines (Shyng 
et al.,1993; Pimpinelli et al., 2005), 
while the receptor, accordingly to 
previous data showing a nuclear 
localization of laminin receptor and 
its interaction with histones 
(Kinoshita et al., 1998; Nikles et al., 
2005), showed a nuclear-like and 
plasma membrane staining pattern 
(Figure 1b). Yellow-orange spots in 
the merged immunofluorescence 
images (Merge) of non-
permeabilized cells in Figure 1b 
(InSet), indicate a fraction of 
37/67kDa LR is also found on the 
plasma membrane with PrPC.  
The Pearson’s Correlation 
Coefficient PCC, produced a value of 
0.78, which reflects the good degree 
of colocalization of the two proteins 
on the cell surface. We estimated, by 
Mander’s Colocalization Coefficient, 
MCC, that 72% of 37/67kDa LR 
colocalized with PrPC on the plasma 
membrane and that 45% of PrPC 
colocalized with 37/67kDa LR. 
These data indicate that the 
remaining 28% of laminin receptor 
could be free to be engaged by other 
interactors, such as laminin-1. 
To assess the precise nature of 
receptor subcellular localization, 
37/67kDa LR co-immunostaining 
was performed also with the antibody 
specific for molecular markers of 
different intracellular organelles, 
such as Golgin (for Golgi apparatus), 
KDEL (for the ER), EEA1 (for early 
endosomes). Transferrin Alexa 488-
conjugated (Tfr) was used to label 
recycling endosomes and Lysotracker 
red for lysosomes (Figure 2). As 
expected, the PCC test produced a 
value close to zero, which indicated 
the absence of laminin receptor in the 
Golgi apparatus, as well as in other 
intracellular organelles.  
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1.2) Interaction between 
37/67kDa laminin receptor 
and PrPC  
In vitro identification of direct and 
heparan sulphate proteoglycan-
dependent interaction sites mediating 
the binding of the cellular PrP to 
laminin receptor (Hundt et al., 2001) 
and the findings concerning the high-
affinity binding curve between GST-
PrP and iodinated laminin receptor 
(Graner et al., 2000), prompt us to 
characterize the interaction between 
37/67kDa LR and PrPC in 
mammalian neuronal and non-
neuronal cells. 
In order to understand whether PrPC 
and 37/67kDa LR entertained 
physical interaction in the cells, we 
subjected them to co-
immunoprecipitation (Co-IP) from 
total cell lysates. Specifically, we 
first immunoprecipitated PrPC from 
lysates and then immuno-identified 
laminin receptor in the precipitate by 
Western blotting. As shown in the 
Figure 3a, the 67kDa isoform of 
laminin receptor could be 
immunoprecipitated with a greater 
extent (compared to immature 37kDa 
LRP) along with PrPC in GT1, as 
well as in HEK-293 cells (Figure 3c), 
whereas the precursor remained in 
major measure in the supernatant 
(SN) of the immunoprecipitate. 
Importantly, to confirm the 
occurrence of the co-
immunoprecipitation, we used an 
anti-laminin receptor antibody in the 
precipitation step and one against 
PrPC to visualize prion protein in the 
Western blotting of the 
immunoprecipitate (Figure 3b).  
To specifically discern the cellular 
compartment involved in 37/67kDa 
LR-PrPC interaction, we performed 
cell-surface co-immunoprecipitation 
assays in the same conditions of the 
previous immunoprecipitation 
experiment with the exception that 
here (Figure 4) the cells were 
incubated on ice with the anti-PrP 
antibody SAF61, before lysis. As 
expected from the 
immunofluorescence data, the two 
proteins were both present at the cell 
surface, and again almost exclusively 
the mature 67kDa LR co-
immunoprecipitated with PrPC on the 
surface of live cells. Calnexin and 
Calreticulin (ER chaperones markers, 
CNX and CLR), which were used as 
control of the specificity of the 
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immunoprecipitation step, were also 
detectable in the immunocomplex. 
The presence of Calnexin and 
Calreticulin in the IP against PrPC 
from the cell surface was unexpected 
and is further discussed below (see 
Discussion). Moreover, we conceive 
that cell surface PrPC is complexed 
with cell surface CRL and CNX, but 
that this doesn’t' show up in whole 
cell immunoprecipitates, because 
during the cell surface binding of 
PrPC with SAF61 antibody we 
selectively enrich the CNX and CLR 
complexed with PrPC on the plasma 
membrane. 
Therefore, in order to ascertain the 
specificity of the Co-IP between LR 
and PrPC, the same membrane used 
for immunoblotting with anti-CNX 
and anti-CLR antibodies, were 
stripped and hybridized with anti-
Golgin antibody, a marker of the 
Golgi apparatus and anti-KDEL and 
ERp57 antibodies to test the presence 
of other Endoplasmic Reticulum-
(ER) proteins in the IP. Protein-A 
beads alone were carried as control 
of the assay (Figure 2b, lane B). 
Notably, as shown in the Fig. 2b, 
Golgin, as well as KDEL and ERp57 
proteins were absent from the PrPC-
37/67kDa LR immunocomplex.  
 
1.3) The 37/67kDa laminin 
receptor inhibitor 
NSC47924 impairs PrPC-
37/67kDa LR binding both 
in vitro and in live cells 
Previous studies demonstrated the 
requirement of the 37/67kDa LR 
system for prion propagation in vitro 
(Rieger et al., 1999; Leucht et al., 
2003). Thus, a possible anti-prion 
therapy approach could target the 
37/67kDa LR to impair 37/67kDa 
LR-PrPC interaction. To this aim, we 
decided to study whether NSC47924, 
an inhibitor of 37/67kDa LR binding 
to laminin-1 (Pesapane et al., 2015), 
and directed to a laminin-active site 
of 37/67kDa LR, which is shared 
with PrPC, influenced the interaction 
between 37/67kDa LR and PrPC and 
eventually their intracellular 
trafficking. NSC47924 is directed to 
the "peptide G" domain of 37kDa 
LRP (aa 161-180), which is also the 
domain of HSPG-independent 
binding of 37/67kDa LR to PrPC 
(Hundt et al., 2001). Since 67kDa LR 
derives from homo or hetero-
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dimerization of 37kDa LRP (Buto et 
al., 1998; Landowski et al., 1995), 
NSC47924 is likely an inhibitor of 
both isoforms. Therefore, the ability 
of NSC47924 to inhibit the binding 
of human recombinant soluble 
37LRP (r37LRP) to human 
recombinant PrP was first evaluated 
by ELISA assays (Figure 5a). 
Purified His-tagged r37LRP was 
incubated on wells pre-coated with 
human recombinant PrP, and binding 
was detected by anti-His HRP. As a 
control for binding specificity, 
r37LRP binding to BSA-coated wells 
was also evaluated in parallel and the 
absorbance readings subtracted. 
r37LRP binding to recombinant PrP 
was specifically inhibited by 
NSC47924. Thus, NSC47924 is a 
specific inhibitor of 37/67kDa LR 
direct binding to PrPC, in vitro. 
To test the compound in live cells, 
we performed co-
immunoprecipitation assays in both 
control condition and treatment of 
GT1 and HEK-293 cells with the 
inhibitor (20 µM NSC47924) 
(IC50=20 µM for inhibition of 
37/67kDa LR binding to laminin-1 
Pesapane et al., 2015). Interestingly, 
the presence of NSC47924 in kinetic 
Co-IP assays (Figure 5b), impaired 
the formation of the 37/67kDa LR-
PrPC immunocomplex in GT1, as 
well as in HEK-293 cells, in a time-
dependent manner; furthermore, 
inhibitor incubation induced a 
decrease of 67kDa LR and a 
progressive and substantial increase 
of PrPC in the immunocomplex 
(Figure 5b, IP lane), as shown by the 
protein ratios plotted in the graphs 
(Figure 5b, right panels).  
 
1.4) The NSC47924 inhibitor 
affects the trafficking of 
37/67kDa LR from the cell 
surface stabilizing PrPC on 
the plasma membrane 
To understand why NSC47924 exerts 
the aforementioned effects and 
dissect the mechanism by which it 
acts in the cells, we decided to 
investigate whether the localization 
and intracellular trafficking of 
37/67kDa LR and PrPC were 
perturbed by the inhibitor treatment.  
Thus, we performed kinetic 
biotinylation assays (Figure 6a) in 
which, GT1 cell surface proteins 
were biotinylated before and after 
inhibitor treatment at different times. 
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37/67kDa LR and PrPC were 
immunoidentified with the specific 
primary antibodies by a Western blot 
analysis on both streptavidin-
immunoprecipitated materials (which 
contains only biotinylated proteins) 
and total cell lysates (which contains 
biotinylated and non-biotinylated 
proteins). We found that the 37kDa 
LRP was the most represented 
isoform both on the plasma 
membrane and in the total cell 
lysates. This latter isoform together 
with the 67kDa LR, starting from 30 
min up to 180 min of NSC47924 
treatment, progressively decreased 
from the cell surface in a time-
dependent manner (Figure 6c), 
possibly due to a stimulated 
internalization and degradation. 
Interestingly, the presence of 
NSC47924 induced stabilization of 
cell surface PrPC (Figure 6b, bottom 
panel), thus reinforcing the results 
found in the Co-IP assays, where the 
presence of 67kDa LR in the 
immunocomplex decreased in favour 
of PrPC (see Figure 5b). 
In parallel, we employed double 
indirect immunofluorescence kinetic 
assays monitoring the presence of 
both 37/67kDa LR and PrPC on the 
cell surface after different times of 
NSC47924 treatment under non-
permeabilized conditions. To this 
aim, GT1 cells were treated or not 
(control) with the inhibitor for the 
same times of the biotinylation 
assays; after that, as shown in Figure 
8, the cells were fixed and processed 
for immunofluorescence to analyse 
the presence of 37/67kDa LR and 
PrPC on the cell surface. In 
agreement with biotinylation 
experiments, we found that while cell 
surface signal of 37/67kDa LR 
decreased on the plasma membrane 
in a time-dependent manner, PrPC 
was stably present on the cell surface 
indicating an opposite effect of the 
compound on the trafficking of the 
two proteins.  
In order to specifically investigate the 
effect of NSC47924 on the 
intracellular fate of the two proteins, 
we performed double indirect 
immunofluorescence assays under 
permeabilized conditions, following 
specifically the cell surface laminin 
receptor and PrPC pools (Figure 7). 
GT1 cells, were first incubated on ice 
(t=0’ at 4 °C, which blocks 
membrane trafficking, Arancibia-
Carcamo et al., 2006) with the 
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primary antibodies against both 
laminin receptor and PrPC and then 
treated at 37 °C (which allows 
membrane trafficking) with or 
without the inhibitor, from 30 min up 
to 180 min, fixed and permeabilized. 
Accordingly, to Co-IP assays, the 
two proteins colocalized on the cell 
surface and already after 30 min at 
room temperature (RT), both 
37/67kDa LR and PrPC entered the 
cells, as shown by the punctate 
staining. The presence of the 
inhibitor, (t=30’ RT, room 
temperature, + NSC47924) induced 
internalization of 37/67kDa LR and a 
decrement of PrPC colocalization, 
which was totally abolished with 
increasing times of inhibitor 
treatment (t=90’ and 180’). The 
disappearance of punctate laminin 
receptor staining which resulted 
somewhat sparse into the cells and 
sharply less intense compared to 
control, supports the results from 
biotinylation kinetics (Figure 5a), 
confirming that the inhibitor 
stimulates 37/67kDa LR 
internalization and possibly its 
degradation, while PrPC was 
stabilized on the cell surface due to 
its prevented internalization. This 
effect could be explained by 
assuming that PrPC becomes not able 
to be internalized because of the 
absence of its receptor. 
To characterize 37/67kDa LR 
internalization in GT1 cells, we 
performed double 
immunofluorescence assays by 
labelling laminin receptor and a 
marker of early endosomal pathway 
EEA1, followed by confocal 
microscopy analysis (Figure 9a). 
Differently from untreated GT1 cells, 
37/67kDa LR colocalized with EEA1 
under NSC47924 treatment. A PCC 
average value higher than 0.6 
(N=100) was found. This partial 
early endosomal accumulation was 
clearly evident after 30 min inhibitor 
treatment. Interestingly, NSC47924 
treatment induced a substantial re-
localization of 37/67kDa LR in the 
endo-lysosomal compartment, as 
indicated by colocalization with 
Lamp-1 in double indirect 
immunofluorescence assays (Figure 
9b). A PCC average value higher 
than 0.7 (N=100) was found after 90 
min and a value of 0.8 after 180 min. 
We confirmed 37/67kDa LR 
internalization via early-endosomes 
(Figure 9b) and its lysosomal-
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mediated degradation (Figure 9b and 
Figure 10a). Indeed, the effect of 
inhibiting lysosomal protein 
degradation on 37/67kDa LR 
fragment generation, was determined 
incubating GT1 cells for 2 days in 
culture medium containing 20 mM 
NH4Cl, in the presence (30’, 180’) or 
not (-) of NSC47924 inhibitor 
(Figure 10 panels c, d). We found 
that NH4Cl treatment resulted in 
accumulation of 37/67kDa LR and 
inhibition of 37/67kDa LR fragment 
generation (180’ NSC47924 control 
versus +NH4Cl, and quantification in 
panel d) implying that NSC47924 
also affects 37/67kDa LR lysosomal-
mediated degradation. Moreover, as 
shown in Fig. 6c, the fragment did 
not reach the cell surface. 
Taken together, these results indicate 
that the inhibitor specifically 
interferes with 37/67kDa LR cell 
surface interaction with PrPC, 
stimulating internalization of both 
37kDa and 67kDa LR isoforms 
suggesting that NSC47924 might act 
through sterical hindrance contrasting 
physiological 37/67kDa LR cell 
surface interaction with laminin-1 
and PrPC. 
Discussion 
Mapping analysis in yeast two-hybrid 
system and cell-binding assay 
identified PrPLRPbd1 (amminoacids 
aa 144-179) as a direct and 
PrPLRbd2 (amminoacids aa 53-93) 
as an indirect HSPG-dependent 
laminin receptor precursor (LRP)-
binding site on PrPC (Hundt et al., 
2001). 
Furthermore, cell-binding and 
internalization studies proved that 
37/67kDa LR acts as the receptor for 
PrPs on the cell surface (Gauczynski 
et al., 2006). Here, we analysed the 
interaction between the non-integrin 
laminin receptor and cellular PrP by 
screening for the binding of all LR 
isoforms with PrPC by co-
immunoprecipitation assays, in both 
neuronal and non-neuronal cell 
systems. Despite previous and 
controversial findings of interaction 
between 37kDa LRP and FLAG-PrP 
in transiently co-transfected COS-7 
cells (Rieger et al., 1997), the 
localization of this interaction and its 
physiopathological role are still 
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debated, therefore our attempt to 
investigate the interaction between 
the two proteins under physiological 
conditions in neuronal cells is novel. 
In particular, we asked whether the 
two proteins interacted in neuronal 
cells, as well as in non-neuronal 
cells, and which of the laminin 
receptor isoforms specifically 
interacted with PrPC. 
Since PrPC is localized on the surface 
of neuronal cells (Stahl et al., 1993; 
Harris et al., 1999) and 37/67kDa LR 
is also present in neuronal cells  
(Douville et al., 1988), we 
hypothesized that the interaction 
between the two proteins could occur 
on the surface of the cells. By double 
immunofluorescence assay in non 
permeabilized cells and a cell-surface 
immunoprecipitation of PrPC 
followed by detection of laminin 
receptor by immunoblotting, we 
could show that the two proteins 
colocalized on the plasma membrane 
and that PrPC preferentially co-
immunoprepitated with the mature 
67kDa LR. 
Interestingly, we detected the 
presence of Calnexin and 
Calreticulin, which are typical 
molecular chaperones resident in the 
ER, in the surface 
immunoprecipitate. This finding was 
(Figure 4) unpredicted regarding the 
co-immunoprecipitation with PrPC, 
but was in agreement with other 
results in which it has been 
demonstrated that typical ER 
proteins, like Calreticulin, could be 
located on the cell surface also 
(Johnson et al., 2001; Itakura et al., 
2013). The marked co-
immunoprecipitation of PrPC with 
Calnexin and Calreticulin on the 
plasma membrane is particularly 
interesting considering that catalysis 
of protein folding is controlled by the 
interaction with these two chaperones 
(Zapun et al., 1998) and that PrPC to 
PrPSc conversion is underlined by 
unfolding process (Sarnataro et al., 
2004). Moreover, the presence of ER 
chaperones CNX and CLR (which 
retains a KDEL signal), in the surface 
Co-IP materials, was specifically 
confirmed by the absence of Golgi 
resident proteins (as Golgin), as well 
as the absence of other ER-resident 
proteins, such as ERp57 (which often 
associates with CNX in the ER), and 
other KDEL proteins. Accordingly, 
to previous results in neuronal cells 
(Itakura et al., 2013), where a 
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significant fraction of CNX was 
found on the cell surface of neurons 
and that ERp57, in contrast to CNX, 
was highly enriched in the non-
synaptic membrane fractions, our 
findings indicate that CNX and 
ERp57 not necessarily follow the 
same fate into the cells.  
Moreover, although CLR is a KDEL 
protein, we found only a negligible 
KDEL band in the Co-IP material. 
The most likely explanation for this 
is that the complex of CLR with cell 
surface PrPC could somehow mask 
the KDEL signal, rendering CLR 
“not well recognizable” by the anti-
KDEL antibody; the chaperons 
proteins might be expressed in 
different isoforms that do not contain 
the ER-retrieval sequence (KDEL) 
(Johnson et al., 2001). Another 
possibility is that CLR might be 
proteolytically processed by ER-
luminal proteases to a form missing 
the KDEL, given that, under ER-
luminal Ca2 concentrations, the C-
domain of the protein containing the 
KDEL amino acid sequence is 
susceptible to proteolysis (Corbett et 
al., 2000). 
 Therefore, Co-IP assays from the 
cell surface give rise to a series of 
questions, among these, whether 
PrPC on the cell surface of GT1 cells 
is properly folded or not. However, 
this phenomenon deserves further 
investigation. 
Although the interaction between 
37/67kDa LR and PrPC has been 
previously proposed, our results 
provide the first clear evidence that 
this interaction occurs on the plasma 
membrane, suggesting that the 67kDa 
LR may act as a PrPC cell surface 
receptor in neuronal mammalian 
cells.  
To analyze the nature of 37/67kDa 
LR-PrPC interaction, we decided to 
study whether the laminin recepotor 
inhibitor NSC47924, targeting the 
peptide G sequence of 37/67kDa LR 
(residues 161-180) able to directly 
bind both laminin-1 (Castronovo et 
al., 1991) and PrPC (Hundt et 
al.,2001), influenced the interaction 
between 37/67kDa LR and PrPC and 
eventually their intracellular 
trafficking. NSC47924 specifically 
inhibited 37/67kDa LR direct binding 
to PrPC in ELISA assays and 
perturbed the interaction between the 
two proteins in live cells also. We 
speculate that is most likely because 
NSC47924 is able to antagonize both 
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the direct, peptide G-mediated, 
37/67kDa LR binding to PrPC and the 
HPSGs-mediated indirect one, which 
occurs in live cells (Hundt et al., 
2001).  
The drug treatment induces cell 
surface disappearance of 37/67kDa 
LR and accumulation in early and 
late endosomes/lysosomes, 
stabilizing cell surface distribution of 
PrPC, suggesting that the inhibitor 
impairs 37/67kDa LR trafficking and 
definitively interaction with PrPC.  
We envisage the following 
hypothesis to explain our findings: 
the inhibitor NSC47924 could exploit 
its effect on the cell surface 
37/67kDa LR by perturbing receptor 
anchorage to both laminin-1 and 
PrPC, thus rendering the 37/67kDa 
LR more prone to be internalized. It 
is likely that this compound could 
exert its effect on both bound and 
free 37/67kDa LR on the cell surface, 
inducing its internalization and 
degradation. However, once 
internalized the 37/67kDa LR 
partially accumulates in EEA1 
enriched-endosomes and, ultimately, 
into endo-lysosomal vesicles. This 
effect dramatically decreases cell 
binding to the laminin of 
extracellular matrix (Pesapane et al., 
2005), for which peptide G is crucial 
(Castronovo et al., 1991). Thus, the 
fact that the presence of 37/67kDa 
LR decreased along with increasing 
times of treatment, resulting in its 
partial early endosomes accumulation 
and progressive late endo-lysosomal 
localization after inhibitor 
incubation, suggests that the 
intracellular trafficking and 
presumably the normal endocytic 
pathway of 37/67kDa LR is altered 
by NSC47924. This compound, 
inducing 37/67kDa LR 
internalization, is able to subtract 
laminin receptor from binding to 
PrPC, which in presence of the 
inhibitor, is no longer able to be 
internalized.  
These findings, on one hand, are very 
crucial if we consider that the main 
function of 37/67kDa LR is to 
enhance tumor cell adhesion to the 
laminin of basement membranes and 
cell migration, two key events in the 
metastasis cascade (Montuori and 
Sobel, 1996). Thus, inhibiting 
37/67kDa LR binding to laminin 
(Zuber et al., 2008; Chetty et al., 
2014), as well as modulating its 
expression on the cell surface and 
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degradation could be a feasible 
approach to block tumor invasion. 
On the other hand, the effect that the 
37/67kDa LR inhibitor exerts on 
PrPC, stabilizing its cell surface 
localization, provides good hopes to 
test it against prion conversion, 
which has been demonstrated to 
occur on the plasma membrane 
(Goold et al., 2011) and/or 
intracellular compartments 
(Marijonovic et al., 2009). However, 
whether the effects we observed, due 
to the inhibitor, could result in a 
stimulus or a stumbling block to 
determine PrPC to PrPSc 
conformational transition has to be 
established with further 
investigations.  
Moreover, the finding that 37/67kDa 
LR may play a role in Alzheimer’s 
disease (AD) (Jovanovic et al., 2015; 
Da Costa Dias et al., 2014) and that 
modulation of 37/67kDa LR could 
affect Aβ cytotoxicity (Da Costa Dias 
et al., 2013; Pinnock et al., 2015) and 
its release from cells (Jovanovic et 
al., 2013), highlights the importance 
of NSC47924 inhibitor to modulate 
37/67kDa LR trafficking and 
degradation, and the consequences 
that this inhibitor could have on other 
neurodegenerative disorders. 
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Figure 1. Expression levels and localization of 37/67kDa LR and PrPC in GT1 and HEK-293 
cells. (a) GT1 and HEK-293 LR cells grown in DMEM supplemented with 10% foetal bovine 
serum, were scraped in lysis buffer and 80µg of total proteins were subjected to SDS-PAGE. 
37/67kDa LR and PrPC were revealed by Western blotting on PVDF and hybridization with a 4290 
pAb and SAF32 mAb, respectively. Molecular weights corresponding to the different bands 
revealed by ECL are indicated and expressed in kDa. (b) GT1 cells grown on coverslips and fixed 
in 4% paraformaldehyde, after 0.1% TX-100 permeabilization (left panel) or under non-
permeabilized conditions (right panel), were double labelled with anti-PrP SAF32 (top panel) or 
SAF61 (bottom panel) antibody and 5004 anti-LR antibody; secondary Ab anti-mouse Alexa-488- 
(green) and anti-rabbit Alexa-546- (red) conjugated were used to reveal PrPC and 37/67kDa LR, 
respectively. Samples were observed using a laser scanning confocal microscope LSM 510 META 
Zeiss. InSet shows 2x zoom of images acquired with a 63x objective lens. Scale bar, 10 µm. 
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Figure 2. 37/67kDa LR does not localize in intracellular compartments.  
GT1 cells grown on coverslips were fixed, permeabilized with TX-100 0.1% for 10 min and 
incubated with anti-37/67kDa LR 5004 pAb and with primary antibodies against different markers 
of intracellular compartments (KDEL, Golgin, EEA1 early endosomes antigen 1). The cells were 
then stained with anti-mouse and anti-rabbit secondary antibody conjugated with Alexa-488 and 
Alexa-546. 
Lysotracker red was used to label lysosomes for 1 hour at 37°C and TfrAlexa-488 to label 
recycling endosomes for 45 min in vivo before fixation and confocal imaging. Scale bar, 10 µm. 
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Figure 3. 37/67kDa LR and PrPC co-immunoprecipitate in GT1 and HEK-293 cells. (a) GT1 
cells were grown on 150 mm dishes, lysed and PrPC was immunoprecipitated using SAF61 mAb. 
37/67kDa LR was revealed using 4290 pAb. The membrane was stripped and blotted with SAF32 
mAb to confirm the occurrence of the immunoprecipitation. L: input, IP: immunoprecipitated, SN: 
supernatant, B: protein-A beads alone. (b) GT1 cells were grown on 150 mm dishes, lysed and 
37/67kDa LR was immunoprecipitated using anti-37/67kDa LR 4290 pAb. PrPC was revealed in 
the immunoprecipitate by western blotting by anti-PrP SAF32 antibody. The membrane was 
stripped and blotted with 4290 pAb to confirm the occurrence of the immunoprecipitation. L: input, 
IP: immunoprecipitated, SN: 1/10 supernatant of immunoprecipitated proteins, B: protein-A beads 
alone. (c). HEK-293 cells were grown and treated as before (fig. 3.a) 
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Figure 4  37/67kDa LR and PrPC co-immunoprecipitate on the surface of GT1 cells. GT1 cells 
grown on 150 mm dishes were first incubated with SAF61 mAb 1 hr at 4°C, then washed and lysed 
in lysis buffer. PrPC was immunoprecipitated with protein-A beads which were loaded on gels and 
transferred to nitrocellulose. Western blotting was performed by incubation with anti-37/67kDa LR 
4290 pAb. To confirm immunoprecipitation the membrane was stripped and probed with anti-PrP 
SAF32 mAb. Calnexin, Calreticulin, Golgin, KDEL and ERp57, were revealed by Western blotting 
with the specific antibodies on the same membranes after stripping. Note the presence of CLR and 
CNX, as well as the absence of Golgin, KDEL and ERp57 in the IP lane. L: input, IP: 
immunoprecipitated, SN: supernatant, B: protein-A beads alone. Anti-KDEL antibody detects two 
bands of ~94kDa and ~78kDa. 
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Figure 5.  37/67kDa LR inhibitor NSC47924 impairs recombinant PrP-r37LRP binding in 
vitro and perturbs co-immunoprecipitation of 37/67kDa LR and PrPC in live cells. (a) Purified 
human His-tagged recombinant 37LRP (r37LRP) was placed for 1 hour at  37°C on wells coated 
with 125 ng of human recombinant PrP, in the presence of 50, 100 and 200 µM NSC47924, or 
DMSO as a vehicle control. Bound r37LRP was revealed by anti-His-HRP and OPD staining; the 
absorbance at 490 nm was measured. r37LRP binding to BSA-coated wells was subtracted to 
obtain specific binding. Values represent the mean±SEM of three experiments carried out in 
triplicate; (*, P< 0.05). (b) Co-IP in GT1 and HEK-293-LR cells was carried out after inhibitor 
treatment in kinetic assays, for indicated times, using anti-PrP SAF32 mAb to immunoprecipiate 
PrPC and anti-37/67kDa LR 4290 pAb to reveal 37/67kDa LR in the IP. Immunoblotting with 
SAF32 mAb was performed to ascertain the occurrence of IP. Calnexin was revealed by stripping 
the same membranes used above, immunoblotted with anti-CNX antibody and revealed with ECL. 
For comparison, signals of CNX are shown to exclude both aspecifics and defect in loading 
samples on gels. 37/67kDa LR/PrPC ratio in the immunocomplex was determined by imposing as 
100% the sum of 37/67kDa LR and PrPC signals in the IP. To calculate ratio, densitometric analysis 
was performed with ImageJ software and values from the mean±SEM of three experiments, were 
considered (P< 0.05). All data were statistically significant 
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Figure 6. The inhibitor NSC47924 interferes with plasma membrane localization of 37/67kDa 
LR. (a) GT1 cell surface proteins were biotinylated at 4°C in control conditions (without inhibitor, 
-) or after 30 min, 90 min and 180 min of treatment with NSC47924 at 37°C, and were recovered 
from cell lysates by immunoprecipitation with streptavidin-beads. Total (80 µg of total cell lysates) 
and cell surface proteins (IP from streptavidin beads), were loaded on gel and processed for SDS-
PAGE and ECL. 37/67kDa LR and PrPC were immunodetected by blotting with 4290 pAb and 
SAF32 mAb, respectively.  
(b) The plot shows the relative percentage of 37/67kDa LR and PrPC on the surface of the cells 
after indicated times of NSC47924 treatment, using as 100% the maximal expression value at cell 
surface in control conditions (- NSC47924). Data are expressed as the means±SEM of three 
independent experiments (*,§, P<0.05). (c) GT1 cell surface proteins were biotinylated at 4°C in 
control conditions (without inhibitor,-) or after 180 min of treatment with NSC47924 at 37°C, cell 
lysates and blot were processed as (a). Note the presence 37/67kDa LR fragment in the total cell 
lysates and its absence on the cell surface (arrow). 
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Figure 7. NSC47924 affects the intracellular fate of 37/67kDa LR and PrPC. GT1 cells were 
grown on coverslips, cooled at 4°C on ice, and stained with SAF32 mAb (1:100) and 5004 pAb 
(1:50)  to label cell surface PrPC and 37/67kDa LR, respectively. To allow membrane trafficking 
and internalization, GT1 cells were warmed at 37 °C in the in culture medium with or without 
NSC47924 for indicated times. After that, the cells were washed, fixed in PFA 4% and 
permeabilized in 0.1% TX-100 for 10 min. To detect internalized proteins the cells were labelled 
with secondary antibodies (PrPC, green; 37/67kDa LR, red) and their colocalization was measured. 
RT: Room Temperature; Scale bars, 10 µm. 
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Figure 8. The inhibitor NSC47924 interferes with cell surface localization of 37/67kDa LR. 
GT1 cells were grown on coverslips and, after treatment with NSC47924 (or not, control-), were 
fixed and processed under non-permeabilized conditions for indirect immunofluorescence by 
labelling 37/67kDa LR (red) and PrPC (green) with respective primary and secondary fluorescent 
antibodies. Nuclei were stained with DAPI. Scale bar, 10 µm. 
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Figure 9. The inhibitor NSC47924 induces 37/67kDa LR and its lysosomal mediated 
degradation. (a) GT1 cells grown on coverslips in both control (without inhibitor) and treated 
conditions (30 min NSC47924) were fixed, permeabilized with TX-100 and probed with 5004 pAb 
and anti-EEA1 mAb to label 37/67kDa LR and early endosomes, respectively. Secondary 
antibodies Alexa-488- and Alexa-546-conjugated were used to visualize 37/67kDa LR and EEA1. 
Nuclei were stained with DRAQ5 dye (blue). Distribution of 37/67kDa LR and EEA1 were 
analyzed by confocal microscopy. Scale bar, 10 µm. (b) GT1 cells grown as before (a) were treated 
with NSC47924 for indicated times and immunostained with anti-37/67kDa LR 5004 antibody 
(green) and anti-Lamp1 (marker of endo-lysosomes, red). Distribution of 37/67kDa LR and Lamp1 
were analyzed by confocal microscopy. Scale bar, 10 µm. 
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Figure 10. NSC47924 induces accumulation of PrPC and lysosome degradation of 37/67kDa 
LR in live cells. (a) GT1 cells grown in 60 mm dishes were treated (30 min, 180 min) or not (-) 
with NSC47924. They were then scraped in lysis buffer and 80µg of total proteins were subjected 
to SDS-PAGE. 37/67kDa LR and PrPC were revealed by Western blotting on PVDF and 
hybridization with a 4290 pAb and SAF32 mAb, respectively. β-tubulin was carried out as loading 
control. Arrow likely points to 37/67kDa LR degradation fragment. (b) Bands corresponding to 
37/67kDa LR and PrPC were quantified imposing as 100% the amount of both proteins in control 
conditions, without NSC47924 (-) (N=3, *P<0.05). (c) GT1 cells were treated as in (a) with the 
exception that here NH4Cl (20 mM, 2 days) was added (+) or not (control) to the culture medium. 
37/67kDa LR was revealed by Western blotting on PVDF and hybridization with a 4290 pAb. Note 
the absence of 37/67kDa LR fragment in NH4Cl panel (arrow). (d) 37/67kDa LR before (-) and 
after (+) 2 days NH4Cl treatment, was quantified imposing as 100% the amount of 37/67kDa LR 
without NSC47924 (-) (N=3, *P<0.05). Since the 37/67kDa LR fragment generates only after 180 
min of NSC47924 treatment, it was quantified, separately from 37/67kDa LR, imposing as 100% 
the amount of fragment under 180’ NSC47924 (control) but without (-) NH4Cl. 
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Results
2.1) Endogenous Shadoo and 
PrPC expression and 
localization in neuronal 
cells 
The endogenous Shadoo, from mouse 
neuronal GT1 cell lysates, migrated 
on SDS-PAGE as different bands 
corresponding, respectively, to the 
glycosylated (~22kDa) and 
unglycosylated (~16kDa) form, as 
shown before (Watts et al., 2007) 
(Figure 2.1a). Furthermore, by 
Western blot analysis with the anti-
Shadoo SPRN-R-12 antibody, 
another band around 12kDa appeared 
on SDS-PAGE 14% polyacrylamide 
gel. Based on the description by 
Premzl et al., 2003, by which Shadoo 
is predicted to have both a signal 
peptide (ER-SP) at aa 25 and a GPI-
AS (attachment signal) at the aa 125 
(human sequence), we reported the 
12kDa isoform as the Shadoo form 
lacking both the ER-SP and the GPI-
AS  
PrPC was typically glycosylated, 
showing different bands ranging 
from  
~27 to ~37 kDa; the unglycosylated 
form which migrates at ~27 kDa, the 
intermediate monoglycosylated form, 
which migrates at 28–30 kDa; and 
the highly glycosylated forms which 
migrate as bands spanning 33–37 
kDa. 
Next, to characterize the subcellular 
distribution of both Shadoo and PrPC 
in GT1 cells, we analyzed their 
localization performing double 
indirect immunofluorescence 
analysis using their respective 
primary antibodies (polyclonal 
SPRN-R12 and monoclonal SAF32 
Abs) followed by fluorescently 
labeled secondary antibodies (Figure 
2.1b). As shown, Shadoo was 
localized both intracellularly, and on 
the plasma membrane with PrPC. In 
order to quantify the amount of 
plasma membrane localized Shadoo, 
we employed biotinylation assays 
which confirmed its cell surface 
localization (Figure 2.1c). 
Interestingly, all Shadoo isoforms, as 
well as for PrPC, were present on the 
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plasma membrane of GT1 cells (see 
the IP lane of Figure 2.2c, left panel).  
 
2.2) Mitochondrial localization 
of Shadoo and TRAP1 
chaperoning 
Based on previous report showing 
that the ER signal peptide of Shadoo 
can mediate targeting to 
mitochondria (Pfeiffer et al., 2013), 
we decided to further explore the 
subcellular localization of 
endogenous Shadoo, using indirect 
immunofluorescence microscopy 
followed by confocal analyses. We 
found that Shadoo colocalized both 
with the ER (PCC = 0.62) and 
mitochondria (PCC =0.88, N=80) 
(Figure 2.2), and by western blot 
analysis of purified mitochondrial 
fraction (Figure 2.3), we found that 
specifically an isoform of Shadoo 
with an electrophoretic motility 
around 18kDa co-purified with 
mitochondria. Reasonably, this latter 
form could likely correspond to the 
non-translocated Shadoo, which 
should retain the N-terminal ER-
signal peptide (ER-SP). 
Furthermore, analyzing the 
fractionation assay (Figure 3), we 
obtained the following informations: 
three isoforms of Shadoo enriched 
the ER, the fully glycosylated 
(22kDa), the unglycosylated 
translocated Shadoo (16kDa, without 
the ER-SP) and the 12kDa isoform 
(lacking both the ER-SP and the GPI-
AS).  
It has been described the presence of 
the mitochondrial chaperone TRAP1 
(Heat shock protein 75 kDa) on the 
outer side of the ER and has a role in 
the quality control of proteins 
destined to the mitochondria 
(Amoroso et al., 2012), for this 
reason, we decided to investigate the 
relationship between TRAP1 and 
Shadoo.  
In order to understand whether 
Shadoo and TRAP1 entertained 
physical interaction in SHSY5Y 
cells, we first subjected them to 
double immunofluorescence analysis 
with anti-Shadoo SPRN-R12 Ab and 
with the mitochondrial marker 
Mitotracker green or with anti-
TRAP1 Ab (Figure 2.4 a,b); in 
parallel, total lysates of SHSY5Y 
cells were processed for co-
immunoprecipitation (Co-IP) assays 
(Figure 2.4c). Specifically, as well as 
for GT1 cells, we were able to show 
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that Shadoo localized in the 
mitochondria also in SHSY5Y cells 
and, by immunoprecipitation analysis 
we first immunoprecipitated TRAP1 
from lysates and then immuno-
identified Shadoo in the precipitate 
by Western blotting with SPRN-R12 
antibody. Importantly, to confirm the 
occurrence of the co-
immunoprecipitation, as control we 
used non-specific immunoglobulins 
(IgM) in the precipitation step or 
protein-A beads alone (Figure 2.4c). 
As deduced by molecular weight 
analysis from electrophoresis and as 
shown in the Figure 2.4c, exclusively 
the non-translocated isoform 
retaining the ER-signal peptide of 
Shadoo (~18kDa, asterisk) could be 
immunoprecipitated along with 
TRAP1, whereas the other isoforms 
remained in the supernatant (SN) of 
the immunoprecipitate.  
2.3) Shadoo DRM-association  
We have previously demonstrated 
that PrPC was localized on the plasma 
membrane of epithelial cells and that 
it was associated with lipid rafts, 
whose perturbation did not affect its 
surface distribution, but rather 
affected its folding (Sarnataro et al., 
2004; Campana et al., 2005), 
rendering PrPC partially resistant to 
PK digestion. On the basis of these 
findings, we asked whether Shadoo 
was associated with lipid rafts and 
they had any role in its metabolism. 
To this aim, we first performed an 
insolubility TX-100 extraction assay, 
finding Shadoo in the insoluble (I) 
material as expected for a DRM-
associated protein (Figure 2.5a). 
Interestingly, all Shadoo isoforms 
were present in the insoluble 
material. Furthermore, to confirm its 
association with lipid rafts, we 
employed floatation-based sucrose 
density gradients in which Shadoo 
was purified by centrifugation to 
equilibrium, as well as Flotillin-2 
(Flot 2) and PrPC, which were used 
as markers of both DRMs and control 
of the procedure (Caputo et al., 
2009). We found that glycosylated 
Shadoo and 12 kDa its isoform 
floated to the lighter fractions of the 
gradients (fractions 4-7) where 
normally DRM-associated proteins 
reside. Notably, both the mature 
glycosylated and the ER-translocated 
isoform of Shadoo (~12kDa) 
associated with DRMs (Figure 2.5b).  
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2.4) Acquisition of “scrapie-
like” properties of Shadoo 
Our previous data showing the 
"protective role" of DRM-association 
in the correct folding of PrPC 
(Sarnataro et al., 2004), together with 
our finding that Shadoo partitioned in 
the DRM fractions of the sucrose 
density gradients, prompted us to 
investigate the folding of Shadoo in 
both GT1 and SHSY5Y cells, as well 
as its “scrapie-like” properties 
(Lehmann and Harris, 1997; Priola 
and Chesebro 1998; Sarnataro et al., 
2004). We reasoned that if Shadoo 
possesses a natural tendency to 
convert to amyloid-like forms in 
vitro (Daude et al., 2010), it should 
be able to acquire “scrapie-like” 
properties also in live cells. To test 
this hypothesis, we first analyzed 
Shadoo sensitivity to PK digestion 
under normal conditions, by using 
PK enzyme on cell lysates. As 
expected by our hypothesis, we 
found that Shadoo was partially 
resistant to PK digestion both at 3.3 
µg/ml and 20 µg/ml (concentrations 
at which PrPC was completely 
sensitive after 2 and 10 min 
treatment) (Sarnataro et al., 2004) 
Figure 2.6a,b. We also analyzed 
Shadoo scrapie-like properties 
evaluating the detergent insolubility 
of the protein by centrifuging 
Triton/DOC lysates at 265,000 g for 
40 minute. Furthermore, 
glycosylated, unglycosylated and 12 
kDa forms of Shadoo were recovered 
in the pellet after ultracentrifugation 
of Triton/Doc lysates of GT1 cells 
(Figure 2.6b), indicating that they 
were aggregated. These two assays 
have been used to identify the 
“scrapie-like” characteristics of prion 
protein and its mutants, because they 
reveal an abnormal folding of the 
protein (Campana et al., 2005). The 
presence of the bands at ~22kDa 
(glycosylated Shadoo), as well as at 
~16kDa and at ~12kDa in the pellet 
of Triton/Doc assay, indicates that 
Shadoo shows a tendency to form 
aggregates into the cells. Overall, 
these data are consistent with a 
proteinase K signature acquisition of 
Shadoo under native conditions 
(Daude et al., 2010).  
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2.5) Role of DRM association in 
Shadoo folding  
To understand in which measure 
association of Shadoo with DRMs 
could be involved in determining the 
folding of the protein, we performed 
a PK assay after cholesterol 
depletion. According to our previous 
findings in epithelial cells (Sarnataro 
et al., 2004), while PrPC was found 
partially PK-resistant only after 2 
min of PK digestion after DRM 
perturbation by cholesterol depletion, 
Shadoo was partially PK-resistant 
already under normal growth 
conditions in neuronal cell lines  and 
its resistance to PK digestion increase 
of about 30% after cholesterol 
depletion by βCD (10’ at 3.3 µg/ml 
PK), respect to control (Figure 2.6. 
right panel). Moreover, in this 
condition we have observed an 
accumulation of 12 kDa isoform of 
Shadoo. Then, we sought to check 
whether in control conditions and 
after perturbation of lipid rafts, the 
protein remained associated with the 
ER chaperones. To test whether 
Shadoo interacted with ER 
chaperones, we performed Co-
immunoprecipitation (Co-IP) assays 
by immunoprecipitating CLR or BiP 
(not shown), with its own antibody 
and revealing Shadoo by Western 
blotting (WB) with SPRN-R12 
antibody (Figure 2.6c). To confirm 
the occurrence of the 
immunoprecipitation, CLR was 
revealed by anti-CLR antibody. 
Interestingly, accordingly with its 
partial resistance to PK digestion 
under normal growth conditions, we 
found that mature glycosylated 
Shadoo Co-IPed with CLR, which 
might be indicative of incorrect 
folding. Furthermore, after DRM 
perturbation by cholesterol depletion, 
the amount of mature Shadoo 
increased in the immunocomplex 
with CLR (about 3-fold respect to 
control) and together with the non-
translocated (18kDa) and ER-
translocated isoforms (12kDa), 
appeared in the immunocomplex. 
Moreover, this isoform was 
accumulated and pk-resistant 
suggesting that suggesting it was 
aggregated. Thus, lipid rafts could be 
involved in the processing of Shadoo. 
However, as we found that in 
cholesterol-depleted cells a major 
portion of the protein was misfolded, 
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our hypothesis was that Shadoo 
possesses a naturally tendency to 
misfold and that the integrity of lipid 
rafts, as well as for PrPC, plays a role 
in its folding and processing.  
The fully glycosylated isoforms, as 
well as the other two Shadoo 
isoforms, interacted in a stronger 
manner with the ER chaperones, after 
DRM perturbation, indicating that, as 
proposed for other polypepdides by 
Brundin et al., 2010, they could 
represent unfolded isoforms of 
“naturally unstructured” Shadoo 
protein which increased after 
perturbation.  
 
2.6) The proteasomal pathway 
in “scrapie-like” properties 
acquisition of Shadoo  
Shadoo was partially localized in the 
ER (Figs. 2 and 3) and it has been 
proposed that ER retention of 
misfolded proteins might lead to 
degradation through the endoplasmic 
reticulum-associated degradation 
(ERAD) pathway, as in the case of 
some pathological PrP mutants 
(Zanusso et al., 1999; Jin et al., 2000; 
Campana et al., 2006). Thus, we 
checked for the role of this pathway 
in the “scrapie-like” properties 
acquisition of Shadoo.  
GT1 cells were treated with the 
proteasome inhibitor ALLN (150 μM 
for 7h) and subjected to PK-assay. 
We found that the band at ~12kDa 
accumulated into the cells (Figure 6d, 
PK-), suggesting that under 
proteasomal block the unglycosylated 
isoform of Shadoo (likely lacking its 
GPI-AS) was not degraded, as it 
should be. Second, by comparing the 
bands of PK digestion under 
proteasomal block (ALLN) to control 
conditions, both mature and 
translocated Shadoo lacking its GPI-
AS, resulted almost completely 
resistant to PK treatment, both after 
2’ and 10’ at 3.3 µg/ml (Figure 6d 
ALLN and compare with control 6a, 
upper panel). While in control 
conditions after 2’ at 20 µg/ml of PK, 
Shadoo resulted almost completely 
digested, we calculated that under 
ALLN about 40% of fully 
glycosylated Shadoo resulted 
resistant to PK treatment and that the 
12 kDa isoform lacking GPI-AS (+/- 
GPI anchor) accumulated (see black 
and white arrowheads in Fig. 6d) and 
were partially PK resistant. To 
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demonstrate that 12kDa isoform was 
specifically degraded by proteasome, 
to exclude the involvement of 
lysosomal-pathway, we performed a 
block of the latter point by NH4Cl (2 
days, 20mM) under control and 
cholesterol depletion conditions 
(Figure 7). In control cells, we found 
that NH4Cl treatment did not result in 
the accumulation of 12 kDa isoform, 
implying that this isoform is 
degraded by proteasome and is not 
generated by a lysosomal 
degradation.  
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Discussion 
 
A depletion in Shadoo, a neuronal 
paralog of PrPC has been 
demonstrated in several experimental 
scrapie-infected rodents and in 
naturally infected scrapie sheep 
(Watts et al., 2011, Westaway et al., 
2011; Sakthivelu et al., 2011). The 
similarity between N-terminals of 
Shadoo and PrPC, together with 
demonstration of their interaction by 
surface plasmon resonance and yeast 
two-hybrid analysis (Jiayu et al., 
2010), suggests that the two proteins 
share biological functions. Thus, a 
functional link between mammalian 
PrP and Shadoo and a possible 
involvement of Shadoo in 
conformational transition of PrPC to 
its misfolded scrapie isoform PrPSc 
has been postulated.  
In line with a previous report (Mays 
et al., 2014), we found that Shadoo 
was expressed as two major bands 
likely corresponding to the 
unglycosylated and glycosylated 
isoforms (Figure 2.1a) and that it was 
partially localized in the ER and 
mitochondria of both GT1 and 
SHSY5Y cells (Figures 2.2 and 2.4).  
Based on previous evidences that  the 
pathogenic effects of PrPSc could be 
related to the presence of misfolded 
forms in the ER (Beranger 2002 et 
al.; Campana et al., 2006) and that 
the ER localization and DRM 
association of PrPC in the early 
secretory pathway was crucial for its 
correct folding (Sarnataro et al., 
2004), our immunofluorescence and 
biochemical assays 
(ER/mitochondria fractionation 
assay) confirmed a partial ER 
localization of Shadoo, except for its 
non-translocated isoform which was 
targeted to mitochondria and 
specifically interacted with the 
molecular chaperone TRAP1. 
Whether TRAP1 could function to 
assist and/or mediate Shadoo 
mitochondrial localization has to be 
established with further 
experimentations.  
However, mitochondrial localization 
of Shadoo was in agreement with a 
recent description that the ER signal 
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peptide of Shadoo, as well as of 
amyloid precursor protein (APP), has 
the property to mediate alternative 
targeting to mitochondria (Pfeiffer et 
al., 2013). The dual targeting to 
either the ER or mitochondria is 
mediated by structural features (α-
helical domains and/or GPI signal 
sequence) within the nascent chain. 
As suggested by Pfeiffer et al., 2013, 
if the protein cannot be productively 
imported because it lacks structured 
domains, then the non-translocated 
polypeptide is released into the 
cytosol where the uncleaved signal 
peptide can mediate targeting to 
mitochondria. Furthermore, as 
previously proposed also for APP 
protein (Pfeiffer et al., 2013), the 
mistargeting of secretory proteins to 
cytosol or mitochondria may 
challenge protein homeostasis and 
cause toxicity, contributing to 
pathomechanisms. Interestingly, we 
found the untranslocated Shadoo 
isoform associated to Calreticulin 
under cholesterol depletion, 
indicating its misfolding. 
Anyway, the question arises as for 
why Shadoo becomes misfolded in 
normal growth conditions. 
It has been proposed that the folding 
of newly synthesized polypeptide 
chains into their native 
conformations, and the unfolding of 
proteins from their native states, 
proceeds through distinct 
intermediates from which derive non-
native oligomeric species of different 
sizes and structures which are able to 
self-associate (Brundin et al., 2010). 
As the polypeptides involved in 
Prion, Parkinson's, Alzheimer's and 
Huntington's diseases populate a 
wide variety of folding intermediates, 
they have a higher propensity to form 
such oligomeric species (Victoria et 
al., 2015). Thus, analyzing our 
results, we propose that Shadoo 
could be a new member of this 
protein family. 
Because the role of lipid rafts has 
never been tested before for Shadoo 
metabolism/processing, we sought to 
check for the association of Shadoo 
with DRMs and their role in its 
folding.  
As expected for a GPI-anchored 
protein, we found Shadoo in the 
insoluble fraction of TX-100 
extraction assay, as well as in the 
lighter fractions of the sucrose 
87 
 
density gradients where normally 
lipid raft-associated proteins float. 
Indeed, to investigate whether 
Shadoo acquired scrapie-like 
characteristics (which implies protein 
misfolding), we analysed its PK 
sensitivity under conditions where 
PrPC was found to be completely 
digested or resistant (Sarnataro et al., 
2004). Strikingly, as clearly shown in 
Figure 2.6 a, Shadoo was found 
partially resistant to PK digestion 
under control conditions and its 
resistance was reinforced by lipid 
rafts perturbation by cholesterol 
depletion. These results are in 
contrast with the behavior of PrPC, 
which in control conditions is 
completely digested by PK, while 
they are in agreement with the fact 
that PrPC becomes partially 
misfolded and PK-resistant after 
DRMs perturbation.  
However, our findings are in line 
with recent data showing that 
recombinant mouse or sheep Shadoo 
converted to an aggregated/amyloid 
form without recourse to chemical 
modification (denaturation or 
acidification, etc.), thus defining a 
proteinase-K signature for Shadoo 
under native conditions (Daude et al., 
2010). In addition, it was interesting 
to note that under cholesterol 
depletion, respect to control 
conditions, the ER-translocated 
Shadoo of 12kDa accumulated.  
However, it is known that proteins 
which do not pass the quality control 
system, are retained in the ER and 
retrotranslocated into the cytosol to 
be then degraded by the proteasome 
(Hampton 2002). Interestingly, the 
ERAD pathway was described to be 
related to the cytotoxicity of PrP (Ma 
and Lindquist, 2001) and to some 
PrP pathological mutants (Zanusso et 
al., 2001). Moreover, in agreement 
with very recent findings which 
describe, in both cultured cells and in 
scrapie-infected rodents, disruption 
of glycosylation and enhancement of 
Shadoo proteasomal degradation 
(Zhang et al., 2014), we found that 
the proteasomal inhibitor ALLN led 
to the accumulation of 12 kDa band 
corresponding to the Shadoo isoform 
which expresses as a doublet band 
(see Figure 2.6d, black and white 
arrowheads, respectively).  This 
doublet could be ascribed to the 
ubiquitination of this Shadoo 
isoform.  
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While confirming the involvement of 
proteasomal pathway in the 
degradation of translocated Shadoo 
isoform, we asked why proteasomal 
block induced a PK-resistance of 
Shadoo.  
One explanation comes from analysis 
Co-IP assays between Shadoo and 
ER chaperones (Figure 2.6c) showing 
that, in normal condition, fully 
glycosylated Shadoo was present in 
the immunocomplex with the ER 
chaperone Calreticulin, strongly 
indicating that Shadoo was 
tendentially unfolded. Furthermore, 
our finding that under cholesterol 
depletion not only translocated 
Shadoo intermediate forms Co-IPed 
with CLR, but also the 
untranslocated one (Figure 2.6c), 
could be explained by the existence 
of cytosolic CLR which can generate 
by an inefficient ER import (Shaffer 
et al., 2005). 
However, the fact that under 
cholesterol depletion the presence of 
mature Shadoo increased in the 
immunocomplex together with its 
non-translocated 18kDa isoform and 
translocated 12kDa one, suggests that 
integrity of lipid rafts has a role in 
the maturation/processing of Shadoo 
and that Shadoo proceeded through 
unfolded aggregated non-native 
isoforms (Brundin et al., 2010). 
Indeed, these isoforms of Sho 
appeared in the pellet of the 
Triton/Doc assay, reinforcing the 
idea that they were aggregated. 
We can conclude that Sho is 
associated to DRMs and acquires 
“scrapie-like” properties in neuronal 
cells. These features fit well to 
protein that belongs to the family of 
intrinsically disordered secretory 
proteins. Moreover, cholesterol 
depletion leads to accumulation of its 
intermediate forms and while ER-
translocated Shadoo lacking the GPI-
AS was degraded via the proteasome, 
block of the latter accounts for the 
accumulation of this form into the 
cells and to the increase of Sho 
misfolding confirmed by the increase 
of its PK-resistance. 
In the light of a very recent finding 
(Ciric et al., 2015) describing a key 
role for Shadoo in the folding 
pathway of PrP, it remains to be 
further investigated which is the 
action of misfolded Shadoo in the 
metabolism of PrPC and/or its 
pathological mutants. 
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Figure 2.1. Shadoo is localized intracellularly and on the plasma membrane of GT1 cells. (a) 
GT1 cells were grown on 60-mm dishes and 80 µg of total cell lysates were loaded on gel, 
subjected to SDS-PAGE (14% polyacrylamide gel) and immunoblotted with the SRNP-R-12 
antibody and SAF32 to reveal Sho and PrPC, respectively with ECL. (b) GT1 cells were grown on 
coverslips, fixed and incubated with R-12 and SAF32 primary antibodies followed by secondary 
antibodies conjugated to Alexa-fluor546 and Alexa-fluor488 to localize Sho and PrPC. Nuclei were 
stained by DRAQ5 dye (blue channel). Scale bars: 10 µm. (c) GT1 cells were grown for 3 days on 
dishes and surface expressed Sho and PrPC were biotinylated. The cell lysates were collected and 
immunoprecipitated (IP) with streptavidin beads. Total cell lysates (80 µg of total proteins), the IP 
(cell surface biotinylated proteins) and supernatant (1/10 of the SN) were loaded on gel and 
transferred to PVDF for Western blotting with R-12 or SAF32 Abs to reveal Sho and PrPC, 
respectively. 
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Figure 2.2. Sho localizes in the ER and mitochondria of GT1 cells. GT1 cells grown on 
coverslips were fixed and probed with anti-Sho R-12 and anti-KDEL primary antibodies followed 
by secondary antibodies conjugated to Alexa-fluor546 (red) and Cy5 (blu) to localize Sho and 
KDEL. To localize mitochondria, Mitotracker green was added to live cells into cell culture 
medium 15 minutes before fixation. PCC is an average value. Scale bars: 10 µm. 
 
 
 
Figure 2.3. The non-translocated Sho isoform is targeted to mitochondria. SHSY5Y cells were 
processed for mitochondria fractionation assay by QproteomeTM Mitochondria Isolation kit from 
Qiagene. Total represents the InPut; Cyt: cytosol and membranes; ER: microsomal fraction; Mito: 
mitochondrial fraction. Western blotting with anti- BiP (ER marker), anti-F1ATPase 
(mitochondrial marker) and anti-GAPDH (cytosolic marker) antibodies were performed as control 
of the procedure. Asterisk indicates the 18kDa non-translocated Shadoo; arrowhead indicates the 
ER-translocated Shadoo lacking GPI-AS(12kDa) 
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Figure 2.4. Shado localizes in mitochondria of SHSY5Y cells and its non-translocated isoform 
co-immunoprecipitates with TRAP1. (a) SHSY5Y cells were grown on coverslips and processed 
as in Figure 2 or (b) were subjected to double immunofluorescence analysis probing with anti-
TRAP1 and anti-Sho R12 Abs followed by secondary Abs conjugated to Alexa-fluor488 and 
Alexa-fluor 546, to reveal TRAP1 (green) and Sho (red) respectively. Brightfield image shows the 
cells. Scale bars: 10 µm. (c) SHSY5Y cells were lysed in Buffer 1X and TRAP1 was 
immunoprecipitated (IP) using the monoclonal anti-TRAP1 Ab (SC-73604). The 
immunoprecipitate was then immunolabeled with the R-12 anti-Sho antibody. (Ig) indicates the 
immunoglobulins and (*) indicates non-translocated Sho (18kDa). To confirm the occurrence of 
the immunoprecipitation, the membranes were probed with the anti-TRAP1 antibody. InPut: 
loading control (50 µg of total lysate); IP: immunoprecipitate;  SN: 1/10 of the supernatant; B: 
protein-A beads alone. 
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Figure 2.5. Shadoo is insoluble in non-ionic detergents and is associated to DRMs. (a) Cells 
from 60-mm dishes were washed twice with PBS and then lysed for 20 min on ice in 1ml of 
Extraction Buffer. After centrifugation of the lysates, the supernatants (S) represent the TX-100 
soluble material. The pellets (I) were then solubilized in 100 µl of solubilization buffer (50 mM 
Tris pH 8.8, 5 mM EDTA, 1% SDS). Proteins were TCA precipitated from the soluble and 
insoluble materials and Sho was revealed by Western blotting. (b) GT1 cells were grown to 
confluence on 150-mm dishes, washed in PBS and lysed for 20 min in TNE/TX-100 1% (25mM 
Tris-HCl pH 7,5, 150mM NaCl, 5mM EDTA, 1%TX-100) on ice (Sarnataro et al., 2002; Broquet 
et al., 2003). A sucrose gradient (5-35% TNE, Top-Bottom) was layered on the top of the lysates 
and one-milliliter fractions (12 fractions in total) were harvested from the top of the gradient. 
Specifically, starting from the top of the gradient the fractions 4-7 (representing DRMs) and 8-12 
(non-DRMs) were collected and loaded on gel. After transfer on PVDF by Western blot, Sho, PrPC 
and Flotillin-2 (Flot2) were revealed by specific antibodies and ECL.  
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Figure 2.6. Lipid rafts perturbation and proteasomal block regulate Shadoo folding and its 
PK- resistance in neuronal cells. (a) Proteinase K (PK) digestion assay. GT1 cells were grown in 
100-mm dishes  in  control (control) or cholesterol depletion conditions (chol. depletion). The cells 
were lysed in Triton/Doc buffer, in the absence of proteases inhibitors, and treated where indicated 
with PK (3.3 µg/ml, 20 µg/ml) at 37°C for 2-10 minutes. The proteins were separated by SDS-
PAGE and immunoblotted. (b) Triton/DOC insolubility assay. After lysis in Triton/DOC buffer, 
lysates of GT1 cells were ultracentrifugated in a TLA 100.3 rotor at 265,000 g and separated into 
soluble (S) and insoluble (P) materials. In (a) and (b) Shadoo and PrPC were revealed by Western  
blotting  by  using  R12 or SAF32 Ab and ECL. The line L represents 80 µg of total cell lysate 
before centrifugation. (c) Analysis of Sho interaction with CLR chaperonine. GT1 cells were 
grown in 100-mm dishes in control, and cholesterol depletion (CD). The cells were then lysates in 
JS buffer and Calreticulin (CLR) was immunoprecipited in nondenaturing conditions. The 
immunoprecipites and 1/10 of the Supernatants (Sup) were loaded on the polyacrylamide gels. The 
gels were releved for the presence of Shadoo and Calreticulin by Western Blotting with the specific 
antibody by ECL. (*, 18kDa) indicates non-translocated Sho and (arrowheads, 12kDa) indicates the 
translocated Sho isoform lacking the GPI-AS. Note the presence of both isoforms in the Co-IP with 
CLR. B: protein-A beads alone indicates non-translocated Sho and (arrowheads, 12kDa) indicates 
the translocated. (d) The proteasomal pathway is involved in Shadoo metabolism and in the PK-
sensitivity of Shadoo. GT1 cells were treated with ALLN (150 µM, 7 hours) and subjected to PK-
assay as in (a). (e) The graph represents percentage of Sho quantified by densitometric analyses 
relative to PK-assays performed in control, chol. depl. or ALLN treated conditions. The amount of 
Sho in not-treated samples (PK -) was considered as 100 %. Results were quantified from three 
different independent experiments and represent the means +/− S.D. All data were statistically 
significant. 
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Figure 2.7. The 12kDa Shadoo isoform accumulates under cholesterol depletion but not 
under  NH4Cl treatment. GT1 cells were grown in 60-mm dishes and NH4Cl was added (+) or not 
(-) to the culture medium. Then the cells were treated or not (control) with β-CD (cholesterol 
depletion). Cells were lysed with Triton/DOC and 80µg of total proteins were subject to SDS-
PAGE. Shadoo was revealed by Western blotting on PVDF and hybridization with SPRN (R-12) 
antibody.  
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FUTURE PRESPECTIVES 
Proposed drugs against TSEs range from small organic compounds to antibodies; 
various therapeutic strategies have been proposed, including blocking the 
conversion of PrPC to PrPSc, increasing PrPSc clearance, and/or stabilizing PrPC. 
While several compounds have been effective in vitro and in animal models, none 
have been proven effective in clinical studies to date. Such lack of in vivo efficacy 
is attributable to high compound toxicity and the lack of permeability of the 
selected compounds across the blood-brain barrier. Interestingly, it has been 
shown that for pathological PrPSc propagation in scrapie-infected neuronal cells is 
required the 37/67kDa laminin receptor (LRP/LR), a non-integrin protein that 
binds both laminin-1 and PrPC (Leucht el al., 2010; Sarnataro et al., 2016, under 
review in Sci. Rep.). Our data reveal NSC47924 as a useful tool to regulate PrPC 
and 37/67kDa LR trafficking and degradation, representing a novel small molecule 
to be tested against prion diseases. The effect that the 37/67kDa LR inhibitor 
exerts on PrPC, stabilizing its cell surface localization, provides good hopes to test 
it against prion conversion, which in a series of conflicting reports has been 
demonstrated to occur on the plasma membrane and/or intracellular compartments 
(Goold et al., 2011; Marijanovic et al., 2009). However, whether the inhibitor 
treatment could result in a stimulus or a stumbling block to determine PrPC to PrPSc 
conformational transition has to be established with further investigations.  
We will investigate the anti-prion activity of the organic compound NSC47924 
and its analogs (NSC1 and NSC2), starting from initial in vitro screening of anti-
amyloid formation, using purified recombinant prion protein, to ex vivo evaluation 
of scrapie conversion in prion infected versus non infected cell lines. We propose 
that a combination of in vitro and ex vivo approaches would be useful for the rapid 
identification of these novel small molecules as anti-prion drug candidates, with 
suitable features that would support their use as in vivo drugs.  
Because of the great experience on prion diseases and the presence of all the 
biosafety level 3 facilities, practices and containment equipment for activities 
involving prion agents, the Chiara Zurzolo’s “Membrane trafficking and 
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Pathogenesis lab” (Pasteur Paris, France) will be chosen for the development of 
this proposal. Our specific aims will be: 
1) Our first objective is to assess whether NSC47924 can effectively inhibit 
the conversion of cellular prion protein (PrPC) into the scrapie prion protein 
(PrPSc) by performing in vitro assays and using ex-vivo non infected 
models.  
2) Another major objective is to study whether NSC47924 can prevent PrPSc 
propagation by using infected ex-vivo models: neuronal GT1 and N2a cells 
infected with scrapie prion protein.  
 
Task 1. Amyloid formation. We will monitor whether NSC47924 can interfere 
with the amyloid formation. We will perform a Thioflavin-T (ThT)- binding assay, 
which is regularly used to quantify the formation and inhibition of amyloid fibrils 
in the presence of anti-amyloidogenic compounds. For this assay we will use 
recMoPrP(23-231) protein (Moda et al., 2015), which is able to convert to amyloid 
fibrils without any seeding factor but is altered by denaturant concentrations, pH 
and buffer composition . The reaction mixtures will be composed by 
recMoPrP(23-231) and an increasing range of NSC47924 concentrations. At 
regular time intervals, the assembly reaction will be monitored using a Thioflavin-
T (ThT)- binding assay (McParland et al, 2000). The binding will be measured by 
averaging the emission fluorescence signal over 60s using a spectofluorometer.  
1.1 PrP conversion: Recently we have found that NSC47924 affects the 
trafficking of PrPC in cultured neuronal GT1 cells stabilizing it on the plasma 
membrane, while inducing internalization and subsequent degradation of 
37/67kDa LR. Thus, we will investigate whether the prion protein that 
accumulated on the plasma membrane after inhibitor treatment, is correctly 
folded or not. To test PrP scrapie properties on the plasma membrane, we will 
biotinylate cell surface proteins and then will immunoprecipitate them with 
streptavidin beads. The immunoprecipitated materials will be subjected to the 
major biochemical assays to evaluate PrP folding:  1) PIPLC sensitivity, 2) 
Triton/Doc Insolubility and 3) Proteinase K (PK) resistance assays.  
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1.2 Prion infection. Moreover, by immunoblotting assays we will test whether 
non-infected GT1 and N2a cells are able to be infected by prions in the 
presence of the drugs. 
 
Task 2. PrPSc spreading: It is known that dendritic cells (DCs) can mediate the 
PrPSc spreading from the intestine to the central nervous system (CNS). To 
examine whether cell-to-cell PrPSc spreading will be affected by NSC47924 
treatment (and or its analogs), we will perform co-culture experiments between 
Dendritic Cells (DCs) loaded with prions and primary neurons in presence or 
absence of inhibitor. This procedure has been widely consolidated in the Zurzolo’s 
lab at Pasteur Institute. To pursue this aim, we will use Alexafluor-labelled PrPSc. 
We will follow the movement of Alexa-PrPSc in live cells (+/- inhibitor) in real 
time using spinning disk confocal microscopy. We will examine scrapie 
production in neuron after inhibitor treatment.  
2.2 PrPSc clearance: In order to understand whether NSC47924 induces PrPSc 
clearance in infected cells (ScGT1 and ScN2a cells), we will quantify the amount 
of PrPSC present in control versus NSC47924 treated cells, using both fluorescence 
microscopy and biochemical approaches. In parallel, we will check also the effects 
of NSC47924 analogs.  
ScGT1 and ScN2a will be cultured from 1 to 4 days in presence or absence 
(control) of NSC47924. We will perform quantitative immunofluorescence assays: 
after fixation, permeabilization and guanidine hydrochloride (GND) treatment, the 
samples will be immunostained for PrP (SAF-32 antibody). Due to the lack of 
PrPSc specific antibodies, a denaturation step of the samples with guanidine 
hydrochloride (Gnd) is required. Immunofluorescence will be acquired using a 
high-field microscope Marianas (intelligent imaging innovation) with a 63x oil. In 
parallel, we will perform also biochemical assays to evaluate clearance of PrPSc 
from prion infected cells treated with inhibitor. Also under this condition, ScGT1 
and ScN2a will be cultured from 1 to 4 days in the presence or absence (control) of 
NSC47924. Then, the levels of PrPSc will be analysed immediately after the 
termination of inhibitor treatment by western blotting. To discriminate PrPSc from 
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PrPC by western blotting, protein lysates will be treated with 20 µ/ml of Proteinase 
K (PK) for 30 min at 37°C and protein content will be pelleted by centrifugation at 
14000 rpm for 1 hour.  In contrast to PrPC, which will be completely degraded by 
PK, only partial degradation of PrPSc occurs in this condition.  
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